WO1994013822A2 - Methods for stable transformation of wheat - Google Patents

Methods for stable transformation of wheat Download PDF

Info

Publication number
WO1994013822A2
WO1994013822A2 PCT/US1993/012085 US9312085W WO9413822A2 WO 1994013822 A2 WO1994013822 A2 WO 1994013822A2 US 9312085 W US9312085 W US 9312085W WO 9413822 A2 WO9413822 A2 WO 9413822A2
Authority
WO
WIPO (PCT)
Prior art keywords
callus
tissue
type
wheat
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/012085
Other languages
French (fr)
Other versions
WO1994013822A3 (en
Inventor
Yin-Fu Chang
James Richard Wong
Andrea Itano
Stephen J. Mejza
Leslie Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26844765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994013822(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Priority to AU57493/94A priority Critical patent/AU688297B2/en
Priority to EP94903608A priority patent/EP0674715B2/en
Priority to DK94903608T priority patent/DK0674715T4/en
Priority to DE69325389T priority patent/DE69325389T3/en
Priority to CA002151127A priority patent/CA2151127C/en
Publication of WO1994013822A2 publication Critical patent/WO1994013822A2/en
Publication of WO1994013822A3 publication Critical patent/WO1994013822A3/en
Anticipated expiration legal-status Critical
Priority to GR990402132T priority patent/GR3031054T3/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C12N15/8207Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0025Culture media for plant cell or plant tissue culture

Definitions

  • the present invention relates to the transformation and regeneration of fertile transformed plants, particularly wheat.
  • Wheat is one of the most important cereal crops in the world. While it is currently being grown in a wide range of environments, the most prominent production of wheat occurs in the USA, China, Australia, Canada, India and Europe.
  • the present invention is drawn to a method for the stable transformation of wheat with nucleic acid sequences of interest and the regeneration of fertile transgenic wheat plants. Particularly it concerns a method for producing stably transformed fertile wheat plants, said method comprising:
  • Type II callus tissue obtained from wheat tissue is bombarded with particles coated with a DNA sequence of interest which sequence comprises a dhfr gene, the bombarded tissue is grown on medium containing methotrexate to selct transformed tissue, and fertile transformed plants are regenerated from said transformed tissue.
  • the wheat tissues are transformed using high velocity microprojectile bombardment and stably transformed plants are regenerated. The method produces stably transformed fertile wheat plants capable of producing progeny which are stably transformed and which express the foreign gene of interest.
  • a rapid, highly efficient method for the stable transformation of wheat cells and the regeneration of transgenic wheat plants involves stably transforming a wheat cell and regenerating wheat plants from transformed wheat cells.
  • fertile transgenic wheat plants can be grown to maturity with a high frequency.
  • the fertile transformed plants are capable of producing transformed progeny that express the foreign gene(s).
  • the method involves subjecting wheat tissues to high velocity projectile bombardment using nucleic acid or particularly, genes of interest.
  • Wheat tissues that are capable of transformation according to the methods of the invention include calli, cell suspension cultures, anthers, microspores, embryos, inflorescences, and the like.
  • Cell suspension cultures can be derived from calli of embryos, leaf tissues, young inflorescences, anthers, etc.
  • Callus can be originated from any tissues of wheat plants including Triticum aestivum and Triticum durum.
  • tissue utilized in initiating callus is immature tissue such as immature embryos, immature inflorescences, and the basal portion of young leaves.
  • callus can be originated from anthers, microspores, mature embryos and in principle any other tissue of wheat capable of forming callus and or secondary embryos.
  • An especially useful tissue for producing regenerable callus is the scutellum of immature wheat embryos.
  • the term callus refers to regenerable callus, further divisible into Type I callus and Type II callus as defined in corn (See, for example. Ozias-Atkins et al.
  • Callus useful in the method of the invention includes Type 1 and Type II callus ( Figure 1) preferably derived from immature embryos, inflorescence, anthers, or leaves, which is induced from explants cultured on a medium containing sucrose or other carbohydrate source.
  • callus which has been derived from immature embryos on a medium containing maltose, hereafter referred to as Type M callus or Type II callus derived on a maltose-containing medium.
  • callus tissue is selected from Type M callus, Type I callus and Type II callus.
  • sucrose has been used almost exclusively as the energy source, usually at levels of 2-3%.
  • a basal medium comprising micronutrients, macronutrients, a carbon source, iron, vitamins, and plant growth regulators.
  • Plant growth regulators are known in the art and include auxins, cytokinins and gibberellins. Such regulators may depend on the step in the process and the particular wheat genotype utilized.
  • Type M callus ( Figure 2) can be obtained directly from culturing immature embryos on maltose-containing medium. The maltose-induced embryo callus is friable, granular with visible somatic embryos, and relatively slow growing. Maltose may be added into the tissue culture medium at a level of about 1 to about 30%, preferably about 11 to about 18%. The exposure time of embryos to maltose may range from about 3 to about 42 days, preferably about 7 to about 28 days.
  • Plant growth regulators useful in the invention include those with auxin-like functions such as IAA, NAA, 2,4-D, 2,4,5-T dicamba, p-chlorophenoxyacetic acid and the like. Such regulators may be added to the maltose-containing medium at a level of about 0.5 mg/1 to about 100 mg/1, preferably about 1 mg/1 to about 40 mg/1, and most preferably about 2 to about 10 mg/1.
  • 2,4-D is the preferred plant growth regulator for inducing Type M callus from wheat immature embryos cultured on a maltose-containing medium.
  • the Type M callus may be used as a target tissue for transformation. It is also used directly in generating cell suspension cultures or in generating Type II callus.
  • Type M callus or Type M-derived Type II callus By utilizing Type M callus or Type M-derived Type II callus, a regenerable cell suspension culture is obtained within 3 months from embryo culture. This is much shorter than the conventional method (at least 6 to 8 months) where sucrose is used as the major carbohydrate source in the medium.
  • the Type M-derived Type II callus and the Type II-derived cell suspension cultures are also highly regenerable. Up to 400 plants can be regenerated per gram (fresh weight) of such Type II callus.
  • Type M callus and Type M-derived Type II callus of the invention yield fertile plants and progeny. In fact, up to about 89% of the plants regenerated from 9-month-old Type M and Type M-derived Type II callus produce seeds.
  • Type M and Type 11 callus, and their derived cell suspension cultures are suitable for transformation. They yield a large number of transformants and fertile plants and progeny.
  • First Type II callus is friable. That is, the callus is characterized as small cell aggregates.
  • the Type II callus of the invention is also highly competent for the establishment of regenerable cell suspension cultures, yields a large number of transformants, is highly regenerable and yields fertile plants and progeny. In general Type II callus culture is more amenable in bombardment protocols and for selection of transformed tissue.
  • the tissue to be transformed is bombarded with a high particle bombardment device.
  • Particle bombardment offers a rapid method for transformation. See, generally, Finer et al. (1992) Plant Cell Reports 11:323-328; Christou P (1990) Physiologia Plantarum 79:210-212; Wang et al. (1988) Plant Molecular Biology 11:433-439; Daniell et al. (1991) Plant Cell Reports 9:615-619; Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309; Klein et al- (1987) Nature 327:70-73; Gordon-Kamm et al.
  • Such disclosed particle gun is capable of introducing particles carrying genetic material into a wide variety of cells.
  • the gun comprises:
  • the gun has a rapid firing cycle as well as a consistent force and accuracy of the shots fired.
  • the gun provides a controlled, reproducible, adjustable and safe propulsion source.
  • An additional benefit of the gun disclosed in WO 93/07256 is that the gun requires less DNA for bombardment than other devices known in the art.
  • other devices for plant cell bombardment as for example the helium powered acceleration system (Sanford et al., Technique-J. Meth. in Cell und Molec. Biol. 3:3-16, 1991) are equally preferred.
  • the tissue is shot at least one time. However, multiple shots of the tissue may be performed to enhance transformation frequency. Thus subjecting the tissue to multiple shots of DNA coated particles constitutes a preferred embodiment of the invention. About two shots per transformation have been demonstrated to yield best results.
  • the particles used as DNA carriers in the bombardments were generally about 0.5 to about 2.0 micron in diameter, more specifically about 1.0 micron.
  • the particles are coated with at least about 0.5 ⁇ g to about 2.0 ⁇ g, preferrably with about 1 ⁇ g DNA per wheight of the particles.
  • Particles useful in the invention are commercially available. For example, gold particles from BioRad Company can be utilized.
  • the particle gun of WO 93/07256 allows for the control of the pressure.
  • a pressure in the range of about 500 psi to about 2500 psi, preferably about 1900 psi may be utilized.
  • the tissue may be subjected to a plasmolysis treatment before bombardment, after bombardment, or preferably both before and after bombardment.
  • Plasmolysis treatment may be performed by diluting cells in a liquid medium with added osmoticum or by transferring cells to semisolid medium containing plasmolyzing agent.
  • the osmoticum can be any sugar such as sorbitol, mannitol, sucrose and the like.
  • the growth medium may additionally comprise auxin.
  • the cells After bombardment the cells are grown for several days in the dark on growth medium with auxin. Typically the cells are grown for about 5 to about 10 weeks, more specifically about 1 to about 7 weeks, before being subjected to selection pressure.
  • a number of selective agents and resistance genes are known in the art. (See, for example, Hauptmann et al. (1988) Plant Physiol. 86: 602-606; Dekeyser et al. (1988) Plant Physiol. 90: 217-223; Eichholtz . et al. (1987) Somatic Cell and Molecular Genetics 13: 67-76; Meijer et al. (1991) Plant Molecular Biology 16: 807-820; and Dekeyser et al.
  • Inhibitors such as amino-glycoside antibiotics which interfere with the translation machinery of prokaryotic and eukaryotic cells, may be utilized. Such inhibitors include kanamycin, G418, hygromycin, etc. Such inhibitors can be inactivated by phosphorylation reactions mediated by the products of either the Tn 5 neomycin phosphotransferase II (npt-II) gene or the hygromycin B resistance gene from E. coli. (See, for example, Herrera-Estrella et al. (1983) EMBO J 2: 987-995; Waldron et al. (1985) Plant Mol Biol 5: 103-108; and the references cited therein.)
  • methotrexate binds to the catalytic site of the dihydrofolate reductase enzyme, resulting in a deficiency of thymidylate and subsequent cell death.
  • chimeric constructs containing a bacterial or mouse dhfr gene can confer resistance to low levels of methotrexate in transformed tobacco, tumip, petunia and rice plants.
  • the transformed and selected tissue After growth on selection medium the transformed and selected tissue is allowed to grow. After several weeks, from about 4 to about 30 weeks, the tissue is transferred to medium for regeneration.
  • transformed wheat plants One of the major obstacles to the production of transformed wheat plants has been methods for regeneration of plants from transformed tissues.
  • transformed callus is grown on either a hormone-free medium containing sucrose, on a medium containing a cytokinin, or on a medium containing auxin and gibberellin. The callus cultures are transferred to the light. Plant development is continued on a hormone-free medium or medium with auxin. After development of roots and shoots, plantlets are transferred to soil and grown to maturity.
  • DNA is extracted from the tissue (callus and plant) and probed to confirm transformation.
  • Methods are available in the art for the isolation of DNA from callus and tissues as well as for confirming the presence of DNA of interest. Such methods to confirm include PCR analysis as well as Southern hybridization. See, Southern, EM (1975) J Mol Biol 98:503 and Mullis, KB (1987) Meth in Enzymology 155:335.
  • any gene of interest can be used in the methods of the invention.
  • a wheat plant can be engineered to express disease and insect resistance genes, genes conferring nutritional value, genes to confer male and/or female sterility, antifungal, antibacterial or antiviral genes, and the like.
  • the method can be used to transfer any nucleic acid to control gene expression.
  • the DNA to be transferred could encode antisense RNA.
  • Type II callus is used as the target tissue.
  • the callus tissue is shot twice with DNA coated 1.0 micron gold particles.
  • Bombardment parameters include 1.0 micron particles; 2 shots per target; 0.6 ⁇ g DNA per shot; 1900 psi; plasmolysis treatment both pre- and post-bombardment.
  • the bombarded tissue is subjected to selection on methotrexate in the range of about 0.1 to about 20 ⁇ g/ml methotrexate, more specifically about 0.5 to about 5 ⁇ g/ml methotrexate for about four months.
  • the tissue is transferred to MS medium containing about 0.1 to about 1.0 mg/1 2,4-D in the dark.
  • the tissue After the tissue has formed embryogenic structures, it is transferred to MS medium containing about 0.5 to about 1 mg/1 NAA, and about 0.5 to about 10 mg/1 GA and placed in the light for about two weeks. After shoot induction the tissues are transferred to MS medium without hormones or half-strength MS containing about 0.1 to about 1 mg/1 NAA for root induction.
  • transformed callus lines are obtained with a high efficiency compared to other published reports. In fact up to 50% efficiency can be seen as confirmed by PCR and/or Southern analysis. Transformation experiments routinely yield stable transformants at a frequency as high as about 50% based on the number of transformants obtained per number of targets shot. Furthermore, by utilizing methotrexate selection, regenerated plants test positive for transformation.
  • the method can be used to transform embryos, mature or immature.
  • spikes from greenhouse grown wheat plants are collected about 10 to about 16, generally about 12 days after anthesis. Kernels are separated from the spikes and surface sterilized. Embryos are then excised and plated on growth medium. 0 to 10 days post excision, DNA is delivered to the embryo using a particle bombardment device. After DNA delivery the embryo or developing callus can be maintained without selection pressure and then the tissue can be regenerated in the presence or absence of selection. Alternatively, plants are regenerated from the bombarded tissue without selection and regenerated plants tested for the presence of the delivered DNA. Improved embryogenic cultures of wheat can be obtained by using previously regenerated material as a source of starting material.
  • Such improved cultures are referred to as "recycled lines" since they are “cycled” through the tissue culture process more than once.
  • the starting material for these improved cultures may be either immature embryos obtained directly from regenerated plants, or the starting material may be seeds from regenerated plants grown as as source of immature embryos.
  • the embryogenic cultures so derived have improved initiation frequency and fertility of regenerants compared to traditional, non-recycled lines. These improvements significantly increase the ease and efficiency with which transgenic wheat and its progeny may be obtained.
  • Figure 1 shows wheat Type II callus induced from immature embryos.
  • Figure 2 shows wheat Type M callus induced from immature embryos.
  • Type M callus globular, somatic embryos developing on the scutellum of certain explants. These calli were removed and placed either on MS medium containing 1.0 to 5.0 mg/1 2,4-D and 2-3% sucrose or on a medium containing a reduced level (5%) of maltose before being placed on the sucrose medium. The material was then subcultured every week to fresh MS medium containing 3% sucrose. II. Genotvpic response of wheat in Type M callus induction.
  • Type M callus formation 10 mg/1 2,4-D plus 13.7% maltose (10MS13.7M) to induce Type M callus formation. After three weeks culture in the dark at 27°C, the induction frequency (%) of Type M callus, Type I callus, as well as non-morphogenic structures from the immature embryos of the tested genotypes were scored.
  • Type M callus induction frequency 52%
  • Type M callus induction frequency 44%
  • the cells for bombardment were given a plasmolysis treatment before and after bombardment. Packed cell volume was measured and cells were diluted in IMS liquid medium with added osmoticum: 0.4M sorbitol for suspension cells and 0.6M sorbitol for callus cells. Cells were diluted such that the final packed cell volume per target was 1/20 ml for a fine suspension and 1/10 ml for callus. Diluted cells were placed in a 250 ml flask containing a stir bar and stirred for a minimum of 30 minutes, up to a few hours. To plate the cells, 2 ml were withdrawn from the flask and pipetted into the top of a vacuum flask onto which a Whatman 2.5 cm GFA filter was placed.
  • the filters were placed on 60x15 mm petri plates containing 5 ml of solid post-bombardment plasmolysis medium, which is IMS containing 0.2M sorbitol for suspension cells, or 0.4M sorbitol for callus cells. Two filters were plated on each dish.
  • pSOG30 is a ⁇ -glucuronidase (Gus) expression vector derived from plasmid pBI121 , purchased from Clontech Laboratories, Palo Alto, California.
  • Intron 6 of the maize Adhl gene was amplified by PCR from plasmid pB428, described in Bennetzen et al, Proc. Natl. Acad. Sc , USA 81: 4125-4128 (1987) and ligated into the BamHl site of pBI121 , which is between the CaMV 35S promoter and the Gus gene.
  • MCMV chlorotic mottle virus
  • pSOG35 is a dihydrofolate reductase (dhfr) expression vector. This construct was derived by fusing the 35S promoter, Adhl intron 6, and MCMV leader described above to the dhfr gene from plasmid pHCO, described in Bourouis and Jarry, EMBO J.
  • the final gene fusion contains the structure: 35S promoter- Adh 1 intron 6-MCMV leader-dhfr-Nos terminator, all in the pUC19 vector backbone.
  • pTG48 comprises the Gus gene under control of the anther specific ant43D promoter and a dhfr gene in a pUC19 backbone. It is the result from the combination of 4 different DNA fragments. Fragment 1 was obtained from pSOG35 after restriction cutting with Hindlll and EcoRI. The EcoRI end of the isolated fragment containing the dhfr gene was adapted to a Sail restriction end.
  • Fragment 2 consisted of the anther specific ant43D promoter isolated from plasmid pCIB 3178 after restriction cutting with Hindlll and Xbal. Plasmid pCIB 3178 is described in detail in the European patent application numer 93810455.1 the relevant parts of which are incorporated herein by reference and was deposited under accession no. NRRL B-18978. Fragment 3 was obtained from plasmid pSOG30 after restriction cutting with Xbal and EcoRI and contained the Gus gene, and fragment 4 corresponded to the commercially available vector pUC19 cut with Sail and EcoRI. VI. Particle Preparation
  • Gold particles (1.0 micron; from Bio-Rad) were washed by aliquoting into a microfuge tube, adding - ⁇ 1 ml 100% ethanol, vortexing, spinning down, removing the supernatant, and repeating twice with sterile water. After the final wash, as much water was removed as possible and polylysine solution (0.02% polylysine + 15mM ammonium acetate) was added to completely immerse the particles. The particles were vortexed, spun, and the supernatant removed. The particles were allowed to dry overnight in a laminar flow hood or for 30 minutes under a gentle nitrogen stream.
  • the petri plate containing the cell filters was inverted onto the platform on top of the stage, and centered over the particle flight opening.
  • the clear lid was placed over the top of the platform.
  • a microprojectile was placed onto the breech pin and the breech closed.
  • the "arm” button was pushed to fill the reservoir with the appropriate amount of helium gas (usually 1800-1900 psi).
  • the vacuum on the chamber was pulled to ⁇ 27 mm. After the vacuum was turned off, and the "arm” and “fire” buttons were pushed. The “arm” button was then pushed to the "off position.
  • Each filter was usually shot twice.
  • 0.5MS maintenance medium which is an aqueous solution of MS salts, vitamins, iron, 3% sucrose, 0.7% agar, 0.5 mg/liter 2,4-D. Tissue was subcultured onto this medium biweekly until embryogenic structures appeared or tissue seemed suitable for regeneration.
  • Tissue was transferred to MS medium containing either 3 mg/liter BAP or 1 mg/liter NAA + 5 mg/liter GA, and plates were moved to the light. After 2-4 weeks, tissue was transferred to MS medium without hormones. Shoots that appeared were placed in containers with either MS medium without hormones or MS medium with 0.5 mg liter NAA. When sufficient root and shoot growth had occurred, plantlets were transferred to soil and placed in a phytotron.
  • Type II callus derived from Type M callus was obtained from immature embryos of the spring wheat genotype UC703 using the methods described above.
  • the resulting callus line, called UC703-0612 was friable, embryogenic, and serially propagated in vitro.
  • a microprojectile device was used to deliver DNA to the Type II callus.
  • pSOG30 and pSOG35 were co-precipitated onto micrometer sized gold particles and introduced into plant cells.
  • Plant SJ3-2A-1 was grown to maturity in a greenhouse and was pollinated with wild- type pollen from UC703 plants. Two seeds developed, from which two immature embryos were excised and germinated. One rescued embryo produced one T ⁇ plant (known as RE1), while the second rescued embryo was placed on callus induction medium and subsequently produced ten T ⁇ plants, two of which are known as RE2 and RE3. Leaf samples from RE1 were assayed for Gus enzyme activity and were positive. PCR analysis for presence of 35S promoter sequences was done on RE1, RE2, and RE3 and all three plants were positive. Southern analysis was done to probe for the presence of the Gus and gene in these three progeny plants, and all three were positive for the gene.
  • T ⁇ plants RE1, RE2, and RE3 (also known as RE2B) were pollinated with wild type UC703 pollen to produce T2 plants. Many seeds developed on each plant and immature embryos were rescued and germinated in vitro. Fluorimetric Gus assays were done and transformants were identified from a segregating population.
  • XII Transformation of wheat by microprojectile bombardment of immature embryos and isolation of transformants without the use of a selectable marker or selection agent.
  • Immature embryos of genotype UC703, 0.75-1.5 mm in length were excised and plated onto MS medium containing 5 mg/liter 2,4-D and 3% sucrose, 30 embryos per plate.
  • Two plasmids were co-precipitated onto micrometer size gold particles and introduced into plant cells by the DuPont Biolistics device using standard techniques as published in the operations manual.
  • One plasmid, pCIB3089 contains the cauliflower mosaic virus 35S promoter (Nature 313:810-812, 1985) fused to the cDNA of the maize anthocyanin regulatory gene B-peru (Plant. Mol. Biol.
  • pCIB4436 contains the CaMV 35S promoter (Nature 313:810-812, 1985) fused to the cDNA of the maize anthocyanin regulatory gene Cl (EMBO Journal 9:2517-2522, 1990; Genes and Development 5:298-309, 1991; and Genes and Development 6:864-875, 1992), with intron #9 of the maize PEP-carboxylase gene (Plant Mol. Biol.
  • T ⁇ generation In order to analyze the T ⁇ generation, fifty-seven immature embryos from this PCR positive plant were excised, germinated, and analyzed. Of these, forty-one T ⁇ plants were PCR positive for both the B-peru and Cl genes. Twenty-two seed-derived T ⁇ plants were also found to be PCR positive for these genes. Southern analysis was done on the parent plant and three PCR positive Tj progeny. All were positive for B-peru and negative for Cl by this analysis. The T2 generation was grown in the greenhouse for seed production.
  • XIII Transformation of wheat by microprojectile bombardment of immature embryos using a high sucrose plasmolysis step prior to gene delivery.
  • Immature embryos (0.75-1.0 mm length) of the wheat genotype UC703 were plated on Murashige and Skoog medium (Physiologia Plantarum 15: 473-497, 1962) containing 3 mg/liter 2,4-D and 3% sucrose. Twenty embryos were placed on each plate of medium. Three days later the immature embryos were transferred to the same medium but containing an additional 15% sucrose in order to plasmolyze the tissue prior to gene delivery.
  • Plasmids pActl-D (The Plant Cell 2:163-171, 1990) and pSOG35 were precipitated onto micrometer size gold particles using standard procedures. Each plate of embryos were shot twice with the DuPont Biolistics helium device using a burst pressure of 900 psi. A total of four target plates were bombarded using the standard 80 mesh screen and four plates were shot without the screen in place. Approximately 4 hours after bombardment the embryos were transferred back to Murashige and Skoog medium containing 3% sucrose.
  • XIV Transformation of wheat by microprojectile bombardment of immature embryos using a high maltose plasmolysis step prior to gene delivery.
  • Immature embryos (0.75-1.0 mm length) of gentotype UC703 were plated on Murashige and Skoog medium containing 3 mg/1 2,4-D and 3% sucrose. After approximately 4 hours the embryos were plated with the embryo axis side down onto plates containing Murashige and Skoog medium with 15% maltose, 3% sucrose and 3 mg/1 2,4-D overlayed with a filter paper supported slab of agarose containing the same components. The embryos were allowed to plasmolyze for 2-3 hours before bombardment. DNA of pActl-D (The Plant Cell 2:163-171, 1990) and pSOG35 was precipitated onto micrometer size gold particles using standard procedures.
  • the responding tissue was placed on Murashige and Skoog medium with 3 mg/1 2,4-D and 3% sucrose with 0.2 mg/1 methotrexate for a 3 week period.
  • the tissue was then placed on a regeneration medium comprised of Murashige and Skoog medium with 1 mg/1 zeatin riboside and 1 mg/1 methotrexate.
  • regenerating plantlets were placed in sterile containers called "GA7s" with half-strength Murashige and Skoog salts, 2% sucrose, 1 mg/1 NAA and either 4 or 8 mg/1 methotrexate.
  • XV Development of improved embryogenic cultures of wheat using previously regenerated material as a culture source.
  • Immature embryos 1-2 mm in size, were removed from caryopses under a dissecting microscope and cultured on a Murashige and Skoog medium with either 5 or 10 mg/1 2,4-D and 13.7 g /l maltose, or on a Murashige and Skoog medium with 2 mg/1 2,4-D and 3% sucrose.
  • This newly induced friable callus now recycled, was transferred to a Murashige and Skoog medium with 1 mg/1 2,4-D and 3% sucrose for maintenance or bombardment experiments.
  • the above plant regeneration and callus induction process were then repeated to produce future generations of friable callus.
  • embryos from wild-type plants were collected and cultured on the same maltose medium.
  • the induction frequency of a friable and embryogenic callus from the embryos was recorded and are shown below.
  • a Type II cell culture (UC703-0612), which was produced from an embryo grown on a maltose-containing medium, was thawed out from cryopreservation and placed on a maintenance medium (Murashige and Skoog medium + 1 mg/1 2,4-D + 3% sucrose). The callus was then placed on a medium containing Murashige and Skoog basal salts and 3 mg/1 6-BAP for plant regeneration. Seeds were harvested from the regenerated plants arid then germinated in soil. For embryo culture, wheat spikes were collected from the seed-derived plants, sterilized with 10% Clorox solution for 10 min, and rinsed several times with sterile water.
  • Immature embryos 1-2 mm in size, were removed from caryopses under a dissecting microscope and cultured on a Murashige and Skoog medium with 2 or 10 mg/1 2,4-D and 13.7 g /l maltose, or on a MS medium with 2 mg/1 2,4-D and 3% sucrose.
  • the induced friable callus was transferred to a MS medium with 1 mg/1 2,4-D and 3% sucrose for maintenance or bombardment experiments.
  • embryos from wild-type plants were collected and cultured on the same maltose medium.
  • the induction frequencies of friable and embryogenic callus from the embryos were recorded and are shown below.
  • XVI Transformation of wheat using a recycled embryogenic culture.
  • a recycled, embryogenic callus line labelled 0612RC was developed as described in the above example.
  • Callus was prepared for bombarding by stirring and plasmolyzing for 2-3 hours in liquid Murashige and Skoog medium containing lmg/1 2,4-D, 3% sucrose and 0.6M sorbitol in a ratio of 1 part cells to 16 parts medium.
  • Each target was prepared by using a vacuum filter appartus to affix 3ml of the cell mixture to glass fiber filters which were then placed onto solid Murashige and Skoog medium with 1 mg/1 2,4-D, 3% sucrose and 0.4M sorbitol.
  • DNA from plasmid pTG48 (ant43/Gus/35Sdhfr) was precipitated onto micrometer size gold particles using 0.1M CaCl2 and 0.1M Na ⁇ PO
  • Each target was shot twice with the microprojectile device described in WO 93/07256 using a gas pressure of 1900 psi.
  • the filters and cells were removed from the sorbitol medium and placed on Murashige and Skoog medium with 1 mg/1 2,4-D and 3% sucrose approximately 24 hours later and allowed to grow for 17 days before placing on the same medium but with lmg/1 methotrexate included.
  • the selection level was increased to 2 mg/1 methotrexate 17 days later.
  • Plantlets were transferred to sterile containers called "GA7s" containing 1/2-strength Murashige and Skoog salts, 2% sucrose and 0.5 mg/1 NAA approximately 20 weeks after bombardment. Plants were transferred to the greenhouse for propagation. Five plants were analyzed by Southerns and the presence of the dhfr gene was confirmed.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Cereal-Derived Products (AREA)
  • Noodles (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)

Abstract

The present invention is drawn to the production of fertile transformed wheat plants. The method involved subjecting wheat tissues to high velocity microprojectile bombardment, selecting for transformed cells, and regenerating stably transformed fertile plants from the transformed cells.

Description

METHODS FOR STABLE TRANSFORMATION OF WHEAT
The present invention relates to the transformation and regeneration of fertile transformed plants, particularly wheat.
Wheat is one of the most important cereal crops in the world. While it is currently being grown in a wide range of environments, the most prominent production of wheat occurs in the USA, China, Australia, Canada, India and Europe.
Most of the wheat production is consumed as flour. Bread wheat accounts for about 80% of total consumption of wheat.
The development of an efficient transformation system is necessary for the molecular analysis of gene expression in plants. In cereal crop plants, this development has been slowed by difficulties encountered in plant regeneration and in the insusceptibility of monocots to Agrobacterium mediated transformation. Most of the progress that has been made in the transformation of cereals has been in producing transgenic rice and maize.
The progress in wheat has been hampered by the inability to establish suitable techniques for the regeneration of fertile plants following transformation.
There are a number of published reports of transient expression of foreign genes in wheat.
However, the only report of stably transformed wheat plants involves a labor intensive method which yields transformants at a low frequency.
Thus, there is a need for biotechnological methods for the development of high-yield, high-nutritional, and disease-resistant wheat varieties. Such methods are necessary to complement the traditional breeding methods currently in use.
The present invention is drawn to a method for the stable transformation of wheat with nucleic acid sequences of interest and the regeneration of fertile transgenic wheat plants. Particularly it concerns a method for producing stably transformed fertile wheat plants, said method comprising:
(a) obtaining wheat tissue;
(b) bombarding said tissue with a DNA sequence of interest; (c) selecting for transformed cells; and,
(d) regenerating fertile transformed plants, wherein said tissue is selected from callus, embryos, anthers, inflorescence, microspores, suspension cells and recycled lines. In a preferred embodiment of the invention Type II callus tissue obtained from wheat tissue is bombarded with particles coated with a DNA sequence of interest which sequence comprises a dhfr gene, the bombarded tissue is grown on medium containing methotrexate to selct transformed tissue, and fertile transformed plants are regenerated from said transformed tissue. The wheat tissues are transformed using high velocity microprojectile bombardment and stably transformed plants are regenerated. The method produces stably transformed fertile wheat plants capable of producing progeny which are stably transformed and which express the foreign gene of interest.
A rapid, highly efficient method for the stable transformation of wheat cells and the regeneration of transgenic wheat plants is provided. The method involves stably transforming a wheat cell and regenerating wheat plants from transformed wheat cells. In addition, using the methods of the invention, fertile transgenic wheat plants can be grown to maturity with a high frequency. The fertile transformed plants are capable of producing transformed progeny that express the foreign gene(s).
The method involves subjecting wheat tissues to high velocity projectile bombardment using nucleic acid or particularly, genes of interest. Wheat tissues that are capable of transformation according to the methods of the invention include calli, cell suspension cultures, anthers, microspores, embryos, inflorescences, and the like. Cell suspension cultures can be derived from calli of embryos, leaf tissues, young inflorescences, anthers, etc.
Callus can be originated from any tissues of wheat plants including Triticum aestivum and Triticum durum. Preferably the tissue utilized in initiating callus is immature tissue such as immature embryos, immature inflorescences, and the basal portion of young leaves. Alternatively, callus can be originated from anthers, microspores, mature embryos and in principle any other tissue of wheat capable of forming callus and or secondary embryos. An especially useful tissue for producing regenerable callus is the scutellum of immature wheat embryos. Herein, the term callus refers to regenerable callus, further divisible into Type I callus and Type II callus as defined in corn (See, for example. Ozias-Atkins et al. (1982) Protoplasma 110:95-105; Maddock et al (1983) J. of Experimental Botany 34(144):915-926; Green (1982) In: Fujiwara A (ed) Proc. 5th Intl. Cong. Plant Tissue and Cell Culture, Maruzen Co., Tokyo, pp. 107-108; Green et al. (1982) In: Downey K et al. (eds) Molecular genetics of Plants and Animals, Miami Winter Symposium Series, Academic Press, New York, pp. 147-157; and Tomes (1985). In: Bright S (ed) Cell Tissue and Cell Culture, Martinus Nijhoff/Dr W Junk Publishers, Dordrecht, The Netherlands, pp. 175-203).
Callus useful in the method of the invention includes Type 1 and Type II callus (Figure 1) preferably derived from immature embryos, inflorescence, anthers, or leaves, which is induced from explants cultured on a medium containing sucrose or other carbohydrate source. Of particular interest is callus which has been derived from immature embryos on a medium containing maltose, hereafter referred to as Type M callus or Type II callus derived on a maltose-containing medium. Thus in the inventive method callus tissue is selected from Type M callus, Type I callus and Type II callus. In plant tissue culture, particularly in cereal immature embryo culture, sucrose has been used almost exclusively as the energy source, usually at levels of 2-3%. Maltose has been reported to have improved green plant regeneration from alfalfa petioles and wheat anthers. (See, for example, Strickland et al. (1987) Plant Science 48:113-121; Stuaπ et al. US Patent 4,801545; Brettell et al. (1990) Plant Cell Reports 9:14-16; Orshinsky et al. (1990) Plant Cell Reports 9:365-369; and Zhou et al. (1991) Plant Cell Reports 10:63-66). It is recognized throughout the steps of the invention that the method involves growth of callus or plant tissues on tissue culture medium. Generally useful throughout the method described herein is the use of a basal medium comprising micronutrients, macronutrients, a carbon source, iron, vitamins, and plant growth regulators. Plant growth regulators are known in the art and include auxins, cytokinins and gibberellins. Such regulators may depend on the step in the process and the particular wheat genotype utilized. Type M callus (Figure 2) can be obtained directly from culturing immature embryos on maltose-containing medium. The maltose-induced embryo callus is friable, granular with visible somatic embryos, and relatively slow growing. Maltose may be added into the tissue culture medium at a level of about 1 to about 30%, preferably about 11 to about 18%. The exposure time of embryos to maltose may range from about 3 to about 42 days, preferably about 7 to about 28 days.
Plant growth regulators useful in the invention include those with auxin-like functions such as IAA, NAA, 2,4-D, 2,4,5-T dicamba, p-chlorophenoxyacetic acid and the like. Such regulators may be added to the maltose-containing medium at a level of about 0.5 mg/1 to about 100 mg/1, preferably about 1 mg/1 to about 40 mg/1, and most preferably about 2 to about 10 mg/1. 2,4-D is the preferred plant growth regulator for inducing Type M callus from wheat immature embryos cultured on a maltose-containing medium. The Type M callus may be used as a target tissue for transformation. It is also used directly in generating cell suspension cultures or in generating Type II callus. By utilizing Type M callus or Type M-derived Type II callus, a regenerable cell suspension culture is obtained within 3 months from embryo culture. This is much shorter than the conventional method (at least 6 to 8 months) where sucrose is used as the major carbohydrate source in the medium. The Type M-derived Type II callus and the Type II-derived cell suspension cultures are also highly regenerable. Up to 400 plants can be regenerated per gram (fresh weight) of such Type II callus.
The Type M callus and Type M-derived Type II callus of the invention yield fertile plants and progeny. In fact, up to about 89% of the plants regenerated from 9-month-old Type M and Type M-derived Type II callus produce seeds. In addition, the Type M and Type 11 callus, and their derived cell suspension cultures are suitable for transformation. They yield a large number of transformants and fertile plants and progeny. There are several advantages to using Type II callus as the target tissue. First Type II callus is friable. That is, the callus is characterized as small cell aggregates. The Type II callus of the invention is also highly competent for the establishment of regenerable cell suspension cultures, yields a large number of transformants, is highly regenerable and yields fertile plants and progeny. In general Type II callus culture is more amenable in bombardment protocols and for selection of transformed tissue.
General references for initiating callus include Green EC (1982) In: Fujiwara A (ed) Proc. 5th Intl. Cong. Plant Tissue and Cell Culture, Maruzen Co., Tokyo, pp. 107-108; and Maddock SE (1987) Plant Cell Rep 6:23-26.); anthers (See, for example Harris et al. (1988) Plant Cell Rep &:337-340, Jahne et al. (1991) Theor. Appl. Genet. 82:74-80, and Sun et al. (1989) Plant Cell Rep 8:313-316.
The tissue to be transformed is bombarded with a high particle bombardment device. Particle bombardment offers a rapid method for transformation. See, generally, Finer et al. (1992) Plant Cell Reports 11:323-328; Christou P (1990) Physiologia Plantarum 79:210-212; Wang et al. (1988) Plant Molecular Biology 11:433-439; Daniell et al. (1991) Plant Cell Reports 9:615-619; Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309; Klein et al- (1987) Nature 327:70-73; Gordon-Kamm et al. (1990) The Plant Cell 2:603-618; Oard et al. (1990) Plant Physiol. 92:334-339; Sanford JC (1990) Plysiologia Plantarum 79:206-209; Fromm et al. (1990) Bio/Technology 8:833-839; Christou et al. (1988) Plant Physiol. 87:671-674; Sautter et al. (1991) Bio/Technology 9:1080-1085; lida et al. (1990) Theor. Appl. Genet. 80:813-816; and Christou et al. (1991) Bio/Technology 9:957-962.
While several particle bombardment devices are disclosed in the literature, a preferred device is the particle gun disclosed in WO 93/07256 herein incorporated by reference. - -) -
Such disclosed particle gun is capable of introducing particles carrying genetic material into a wide variety of cells. The gun comprises:
* a flying block to accelerate and direct particles carrying genetic material;
* an inert gas driven launch device capable of precise flying block velocity control;
* a stop/stripping arrangement to stop the flying block and allow free flight of the particles coated with genetic material toward intact cells; and
* attendant locks and safety features.
The gun has a rapid firing cycle as well as a consistent force and accuracy of the shots fired. The gun provides a controlled, reproducible, adjustable and safe propulsion source. An additional benefit of the gun disclosed in WO 93/07256 is that the gun requires less DNA for bombardment than other devices known in the art. However, other devices for plant cell bombardment as for example the helium powered acceleration system (Sanford et al., Technique-J. Meth. in Cell und Molec. Biol. 3:3-16, 1991) are equally preferred. Generally the tissue is shot at least one time. However, multiple shots of the tissue may be performed to enhance transformation frequency. Thus subjecting the tissue to multiple shots of DNA coated particles constitutes a preferred embodiment of the invention. About two shots per transformation have been demonstrated to yield best results. The particles used as DNA carriers in the bombardments were generally about 0.5 to about 2.0 micron in diameter, more specifically about 1.0 micron. The particles are coated with at least about 0.5 μg to about 2.0 μg, preferrably with about 1 μg DNA per wheight of the particles. Particles useful in the invention are commercially available. For example, gold particles from BioRad Company can be utilized.
The particle gun of WO 93/07256 allows for the control of the pressure. A pressure in the range of about 500 psi to about 2500 psi, preferably about 1900 psi may be utilized. The tissue may be subjected to a plasmolysis treatment before bombardment, after bombardment, or preferably both before and after bombardment. Plasmolysis treatment may be performed by diluting cells in a liquid medium with added osmoticum or by transferring cells to semisolid medium containing plasmolyzing agent. Generally the osmoticum can be any sugar such as sorbitol, mannitol, sucrose and the like. The growth medium may additionally comprise auxin.
After bombardment the cells are grown for several days in the dark on growth medium with auxin. Typically the cells are grown for about 5 to about 10 weeks, more specifically about 1 to about 7 weeks, before being subjected to selection pressure. A number of selective agents and resistance genes are known in the art. (See, for example, Hauptmann et al. (1988) Plant Physiol. 86: 602-606; Dekeyser et al. (1988) Plant Physiol. 90: 217-223; Eichholtz. et al. (1987) Somatic Cell and Molecular Genetics 13: 67-76; Meijer et al. (1991) Plant Molecular Biology 16: 807-820; and Dekeyser et al. (1989) 90: 217-223.) Inhibitors such as amino-glycoside antibiotics which interfere with the translation machinery of prokaryotic and eukaryotic cells, may be utilized. Such inhibitors include kanamycin, G418, hygromycin, etc. Such inhibitors can be inactivated by phosphorylation reactions mediated by the products of either the Tn 5 neomycin phosphotransferase II (npt-II) gene or the hygromycin B resistance gene from E. coli. (See, for example, Herrera-Estrella et al. (1983) EMBO J 2: 987-995; Waldron et al. (1985) Plant Mol Biol 5: 103-108; and the references cited therein.)
Additionally, selective agents such as bleomycin, methotrexate, and phosphinothricin can be utilized. Favorable results have been achieved utilizing methotrexate. Methotrexate binds to the catalytic site of the dihydrofolate reductase enzyme, resulting in a deficiency of thymidylate and subsequent cell death. (Weikheiser, WC (1961) J Biol Chem 236: 888-893.) Reports in the literature indicate that chimeric constructs containing a bacterial or mouse dhfr gene can confer resistance to low levels of methotrexate in transformed tobacco, tumip, petunia and rice plants. (See, DeBlock et al. EMBO J 3: 1681-1689; Brisson et al. Nature 310: 511-514; Eichholtz et al. (1987) Somatic Cell and Molecular Genetics 13: 67-76; and Dekeyser et al. (1989) Plant Physiol. 90: 217-223.). Media comprising methotrexate or hygromycin are preferred media for the selecting step involved in growing transformed tissue.
After growth on selection medium the transformed and selected tissue is allowed to grow. After several weeks, from about 4 to about 30 weeks, the tissue is transferred to medium for regeneration.
One of the major obstacles to the production of transformed wheat plants has been methods for regeneration of plants from transformed tissues. Generally for plant regeneration, transformed callus is grown on either a hormone-free medium containing sucrose, on a medium containing a cytokinin, or on a medium containing auxin and gibberellin. The callus cultures are transferred to the light. Plant development is continued on a hormone-free medium or medium with auxin. After development of roots and shoots, plantlets are transferred to soil and grown to maturity.
At several stages along the process, DNA is extracted from the tissue (callus and plant) and probed to confirm transformation. Methods are available in the art for the isolation of DNA from callus and tissues as well as for confirming the presence of DNA of interest. Such methods to confirm include PCR analysis as well as Southern hybridization. See, Southern, EM (1975) J Mol Biol 98:503 and Mullis, KB (1987) Meth in Enzymology 155:335.
As will be evident to one of skill in the art, now that a method has been provided for the stable transformation of wheat, any gene of interest can be used in the methods of the invention. For example, a wheat plant can be engineered to express disease and insect resistance genes, genes conferring nutritional value, genes to confer male and/or female sterility, antifungal, antibacterial or antiviral genes, and the like. Likewise, the method can be used to transfer any nucleic acid to control gene expression. For example, the DNA to be transferred could encode antisense RNA.
In one embodiment of the invention, Type II callus is used as the target tissue. The callus tissue is shot twice with DNA coated 1.0 micron gold particles. Bombardment parameters include 1.0 micron particles; 2 shots per target; 0.6μg DNA per shot; 1900 psi; plasmolysis treatment both pre- and post-bombardment. About 14 days post-bombardment, the bombarded tissue is subjected to selection on methotrexate in the range of about 0.1 to about 20 μg/ml methotrexate, more specifically about 0.5 to about 5 μg/ml methotrexate for about four months. To regenerate fertile wheat plants from the transformed cells, the tissue is transferred to MS medium containing about 0.1 to about 1.0 mg/1 2,4-D in the dark. After the tissue has formed embryogenic structures, it is transferred to MS medium containing about 0.5 to about 1 mg/1 NAA, and about 0.5 to about 10 mg/1 GA and placed in the light for about two weeks. After shoot induction the tissues are transferred to MS medium without hormones or half-strength MS containing about 0.1 to about 1 mg/1 NAA for root induction.
Utilizing the methods described herein, transformed callus lines are obtained with a high efficiency compared to other published reports. In fact up to 50% efficiency can be seen as confirmed by PCR and/or Southern analysis. Transformation experiments routinely yield stable transformants at a frequency as high as about 50% based on the number of transformants obtained per number of targets shot. Furthermore, by utilizing methotrexate selection, regenerated plants test positive for transformation.
In another embodiment, the method can be used to transform embryos, mature or immature. In this method, spikes from greenhouse grown wheat plants are collected about 10 to about 16, generally about 12 days after anthesis. Kernels are separated from the spikes and surface sterilized. Embryos are then excised and plated on growth medium. 0 to 10 days post excision, DNA is delivered to the embryo using a particle bombardment device. After DNA delivery the embryo or developing callus can be maintained without selection pressure and then the tissue can be regenerated in the presence or absence of selection. Alternatively, plants are regenerated from the bombarded tissue without selection and regenerated plants tested for the presence of the delivered DNA. Improved embryogenic cultures of wheat can be obtained by using previously regenerated material as a source of starting material. Such improved cultures are referred to as "recycled lines" since they are "cycled" through the tissue culture process more than once. The starting material for these improved cultures may be either immature embryos obtained directly from regenerated plants, or the starting material may be seeds from regenerated plants grown as as source of immature embryos. The embryogenic cultures so derived have improved initiation frequency and fertility of regenerants compared to traditional, non-recycled lines. These improvements significantly increase the ease and efficiency with which transgenic wheat and its progeny may be obtained. Having generally described the invention, the following examples are offered by way of illustration and not by way of limitation.
BRIEF DESCRIPTION OF THE FIGURES:
Figure 1 shows wheat Type II callus induced from immature embryos.
Figure 2 shows wheat Type M callus induced from immature embryos.
EXAMPLES:
I. Preparation of wheat callus, genotype UC703
Wheat plants of genotype UC703 were grown to flowering and self-pollinated. Spikes containing embryos 1 to 2.5 mm in length were removed from the plants and sterilized with 10% Clorox solution for 10 minutes. Embryos were removed from the immature seeds and placed with the embryo axis downwards on the medium of Murashige and Skoog containing 5 or 10 mg/1 2,4-D, 13.7% w/v maltose, 100 mg/1 proline and 100 mg/1 myo-inositol solidified with 0.7-0.8% w/v phytagar or 0.1-0.2% gelrite (initiation medium). After a three week culture in the dark at 27°C, a preferred callus was recognized by the presence of well formed globular, somatic embryos (Type M callus) developing on the scutellum of certain explants. These calli were removed and placed either on MS medium containing 1.0 to 5.0 mg/1 2,4-D and 2-3% sucrose or on a medium containing a reduced level (5%) of maltose before being placed on the sucrose medium. The material was then subcultured every week to fresh MS medium containing 3% sucrose. II. Genotvpic response of wheat in Type M callus induction.
Wheat plants of genotype UC703, MIT, Orofen, Yecoro rojo and Chris were grown to flowering and self-pollinated. Immature embryos were removed from spikes and cultured on a Murashige and Skoog medium containing:
1 mg/1 2,4-D plus 2% sucrose (IMS),
1 mg/1 2,4-D plus 2% maltose (1MS2M),
1 mg/1 2,4-D plus 9% maltose (1MS9M),
1 mg/1 2,4-D plus 13.7% maltose (lMS13.7M),or
10 mg/1 2,4-D plus 13.7% maltose (10MS13.7M) to induce Type M callus formation. After three weeks culture in the dark at 27°C, the induction frequency (%) of Type M callus, Type I callus, as well as non-morphogenic structures from the immature embryos of the tested genotypes were scored.
Genotype name
UC703
UC703
UC703
UC703
MIT
MIT
MIT
MIT
Orofen
Orofen
Yecoro rojo
Yecoro rojo
Figure imgf000011_0001
HI. Type M callus induction frequency from wheat genotype UC703.
Wheat plants of genotype UC703 were grown to flowering and self -pollinated. Immature embryos were removed from the spikes and placed with the embryo axis downwards on the medium of Murashige and Skoog (MS) containing 5 or 10 mg/1 2,4-D and 13.7% w/v maltose solidified with 0.8% phytagar. After 3 weeks culture in the dark at 27°C, the Type M callus induction frequency from the cultured immature embryos was scored. Medium 1. MS + 5 mg/1 2,4-D + 13.7% maltose
Figure imgf000012_0001
Type M callus induction frequency: 52%
Medium 2. MS + 10 mg/1 2,4-D + 13.7% maltose
No. of embryos produced Type M callus
184
175
41
Figure imgf000012_0002
400
Type M callus induction frequency: 44%
IV. Cell Preparation for Bombardment
The cells for bombardment were given a plasmolysis treatment before and after bombardment. Packed cell volume was measured and cells were diluted in IMS liquid medium with added osmoticum: 0.4M sorbitol for suspension cells and 0.6M sorbitol for callus cells. Cells were diluted such that the final packed cell volume per target was 1/20 ml for a fine suspension and 1/10 ml for callus. Diluted cells were placed in a 250 ml flask containing a stir bar and stirred for a minimum of 30 minutes, up to a few hours. To plate the cells, 2 ml were withdrawn from the flask and pipetted into the top of a vacuum flask onto which a Whatman 2.5 cm GFA filter was placed. The vacuum was applied until the cells were dried onto the filter. The filters were placed on 60x15 mm petri plates containing 5 ml of solid post-bombardment plasmolysis medium, which is IMS containing 0.2M sorbitol for suspension cells, or 0.4M sorbitol for callus cells. Two filters were plated on each dish.
V. Vectors used for bombardment
The following plasmids were used for particle bombardment: pSOG30 is a β-glucuronidase (Gus) expression vector derived from plasmid pBI121 , purchased from Clontech Laboratories, Palo Alto, California. Intron 6 of the maize Adhl gene was amplified by PCR from plasmid pB428, described in Bennetzen et al, Proc. Natl. Acad. Sc , USA 81: 4125-4128 (1987) and ligated into the BamHl site of pBI121 , which is between the CaMV 35S promoter and the Gus gene. A 17 bp maize chlorotic mottle virus (MCMV) leader, described in Lommel et al., Virology 181: 382-385 (1991), was inserted into the 35S-Gus gene non-translated leader. The final gene fusion contains the structure: 35S promoter- Adhl intron 6-MCMV leader-Gus-Nos terminator, all in the pUC19 vector backbone. pSOG35 is a dihydrofolate reductase (dhfr) expression vector. This construct was derived by fusing the 35S promoter, Adhl intron 6, and MCMV leader described above to the dhfr gene from plasmid pHCO, described in Bourouis and Jarry, EMBO J. 2: 1099-1 104 (1983). The final gene fusion contains the structure: 35S promoter- Adh 1 intron 6-MCMV leader-dhfr-Nos terminator, all in the pUC19 vector backbone. pTG48 comprises the Gus gene under control of the anther specific ant43D promoter and a dhfr gene in a pUC19 backbone. It is the result from the combination of 4 different DNA fragments. Fragment 1 was obtained from pSOG35 after restriction cutting with Hindlll and EcoRI. The EcoRI end of the isolated fragment containing the dhfr gene was adapted to a Sail restriction end. Fragment 2 consisted of the anther specific ant43D promoter isolated from plasmid pCIB 3178 after restriction cutting with Hindlll and Xbal. Plasmid pCIB 3178 is described in detail in the European patent application numer 93810455.1 the relevant parts of which are incorporated herein by reference and was deposited under accession no. NRRL B-18978. Fragment 3 was obtained from plasmid pSOG30 after restriction cutting with Xbal and EcoRI and contained the Gus gene, and fragment 4 corresponded to the commercially available vector pUC19 cut with Sail and EcoRI. VI. Particle Preparation
Gold particles (1.0 micron; from Bio-Rad) were washed by aliquoting into a microfuge tube, adding -~1 ml 100% ethanol, vortexing, spinning down, removing the supernatant, and repeating twice with sterile water. After the final wash, as much water was removed as possible and polylysine solution (0.02% polylysine + 15mM ammonium acetate) was added to completely immerse the particles. The particles were vortexed, spun, and the supernatant removed. The particles were allowed to dry overnight in a laminar flow hood or for 30 minutes under a gentle nitrogen stream.
For a "full" particle preparation, 10 mg particles were weighed out and placed in a sterile microfuge tube containing a stir bar. 100 μl (1 μg/μl) DNA was added, followed by vortexing. Then, 10 μl 100 mM Na2HPO4 was added, followed by vonexing. 10 μl 100 mM CaCl2 was added, followed by vortexing. Finally, 380 μl 100% ethanol was added, followed by vortexing. While the suspension was stirred vigorously, 3 μl were pipetted onto plastic fliers (projectiles). The particles were allowed to dry onto fliers for at least 15 minutes before bombarding.
VII. Bombarding Cell Cultures
The petri plate containing the cell filters was inverted onto the platform on top of the stage, and centered over the particle flight opening. The clear lid was placed over the top of the platform. A microprojectile was placed onto the breech pin and the breech closed. The "arm" button was pushed to fill the reservoir with the appropriate amount of helium gas (usually 1800-1900 psi). The vacuum on the chamber was pulled to ~27 mm. After the vacuum was turned off, and the "arm" and "fire" buttons were pushed. The "arm" button was then pushed to the "off position. Each filter was usually shot twice.
VIII. Post-bombardment Culture and Selection
After bombardment the cells were kept in the dark overnight. The next day, filters were removed from plasmolysis medium and placed on IMS medium. Selection was applied 7-10 days post-bombardment for suspension cells and after 14 days for callus cells. Cells were scraped off the filters and spread onto the surface of plates containing IMS plus 2 mg/liter methotrexate. (Transformants were obtained by initially selecting at 4 mg/liter methotrexate also.) Plates were incubated in the dark for several weeks. Resistant colonies that arise after a few weeks were transferred to IMS + 4 mg/1 methotrexate. Colonies that continue to proliferate for about 3-4 weeks are then transferred to "0.5MS" maintenance medium, which is an aqueous solution of MS salts, vitamins, iron, 3% sucrose, 0.7% agar, 0.5 mg/liter 2,4-D. Tissue was subcultured onto this medium biweekly until embryogenic structures appeared or tissue seemed suitable for regeneration.
IX. Regeneration
Tissue was transferred to MS medium containing either 3 mg/liter BAP or 1 mg/liter NAA + 5 mg/liter GA, and plates were moved to the light. After 2-4 weeks, tissue was transferred to MS medium without hormones. Shoots that appeared were placed in containers with either MS medium without hormones or MS medium with 0.5 mg liter NAA. When sufficient root and shoot growth had occurred, plantlets were transferred to soil and placed in a phytotron.
X. Transformant Analysis
About 20 mg callus tissue was used for PCR analysis. DNA was extracted using a quick phenol/chloroform tisoamyl alcohol method and 2 μl was used per reaction. Primers were designed to amplify the region from the 5' end of the adh gene to the 3' end of the dhfr gene.
XI: Transformation of wheat by microprojectile bombardment of Type II callus derived from Type M callus.
Type II callus derived from Type M callus was obtained from immature embryos of the spring wheat genotype UC703 using the methods described above. The resulting callus line, called UC703-0612, was friable, embryogenic, and serially propagated in vitro. A microprojectile device was used to deliver DNA to the Type II callus. pSOG30 and pSOG35 were co-precipitated onto micrometer sized gold particles and introduced into plant cells.
Two weeks after bombardment, cells were transferred to callus maintenance medium containing 4 mg/liter methotrexate. Resistant colonies that proliferated were subcultured over a period of months and then regenerated in the absence of methotrexate. PCR analysis was done on callus samples to confirm the presence of the dhfr gene. One colony, SJ3-2A, produced a TQ plant (SJ3-2A-1) in vitro that was eventually transferred to soil and grown in the greenhouse. Leaf samples from this plant were assayed for Gus enzyme activity using standard protocols (Jefferson, Plant Molecular Biology Reporter Vol. 5, No. 4, 1987) and were positive. DNA was extracted from this plant and Southern analysis confirmed the presence of the dhfr gene.
Plant SJ3-2A-1 was grown to maturity in a greenhouse and was pollinated with wild- type pollen from UC703 plants. Two seeds developed, from which two immature embryos were excised and germinated. One rescued embryo produced one T\ plant (known as RE1), while the second rescued embryo was placed on callus induction medium and subsequently produced ten T\ plants, two of which are known as RE2 and RE3. Leaf samples from RE1 were assayed for Gus enzyme activity and were positive. PCR analysis for presence of 35S promoter sequences was done on RE1, RE2, and RE3 and all three plants were positive. Southern analysis was done to probe for the presence of the Gus and gene in these three progeny plants, and all three were positive for the gene. T\ plants RE1, RE2, and RE3 (also known as RE2B) were pollinated with wild type UC703 pollen to produce T2 plants. Many seeds developed on each plant and immature embryos were rescued and germinated in vitro. Fluorimetric Gus assays were done and transformants were identified from a segregating population.
XII: Transformation of wheat by microprojectile bombardment of immature embryos and isolation of transformants without the use of a selectable marker or selection agent.
Immature embryos of genotype UC703, 0.75-1.5 mm in length, were excised and plated onto MS medium containing 5 mg/liter 2,4-D and 3% sucrose, 30 embryos per plate. Two plasmids were co-precipitated onto micrometer size gold particles and introduced into plant cells by the DuPont Biolistics device using standard techniques as published in the operations manual. One plasmid, pCIB3089, contains the cauliflower mosaic virus 35S promoter (Nature 313:810-812, 1985) fused to the cDNA of the maize anthocyanin regulatory gene B-peru (Plant. Mol. Biol. 17:127-130, 1991 and Genes and Development 6:864-875, 1992), with intron #2 from alcohol dehydrogenase 1 gene (Nucleic Acid Research 12:3983-4000, 1984) placed between the 3' end of the coding sequence and 5' to the 35S terminator sequence. The other plasmid, pCIB4436, contains the CaMV 35S promoter (Nature 313:810-812, 1985) fused to the cDNA of the maize anthocyanin regulatory gene Cl (EMBO Journal 9:2517-2522, 1990; Genes and Development 5:298-309, 1991; and Genes and Development 6:864-875, 1992), with intron #9 of the maize PEP-carboxylase gene (Plant Mol. Biol. 12:579-589, 1989) placed between the 3' end of the coding sequence and 5' to the 35 S terminator. Together, these two genes perform as a scorable marker for transformation. After 22 days, embryos were scored for Type I callus response and callus was transferred to a proliferation medium. Twenty of ninety-four embryos showed a Type I callus response. Tissue from eleven of the twenty responding embryos was transferred to plant regeneration medium about one month later. Eleven plants were grown to maturity in the greenhouse and all plants set seed. One plant (JN11-1800- 3#1) produced reddish-colored seed, presumably caused by expression of one or more of the inserted regulatory genes. Five DNA samples were obtained from this plant and PCR analysis was done to check for the presence of the 35S promoter, the Cl gene, and the B-peru gene. The PCR results were positive for these sequences in three independent reactions.
In order to analyze the T\ generation, fifty-seven immature embryos from this PCR positive plant were excised, germinated, and analyzed. Of these, forty-one T\ plants were PCR positive for both the B-peru and Cl genes. Twenty-two seed-derived T\ plants were also found to be PCR positive for these genes. Southern analysis was done on the parent plant and three PCR positive Tj progeny. All were positive for B-peru and negative for Cl by this analysis. The T2 generation was grown in the greenhouse for seed production.
XIII: Transformation of wheat by microprojectile bombardment of immature embryos using a high sucrose plasmolysis step prior to gene delivery.
Immature embryos (0.75-1.0 mm length) of the wheat genotype UC703 were plated on Murashige and Skoog medium (Physiologia Plantarum 15: 473-497, 1962) containing 3 mg/liter 2,4-D and 3% sucrose. Twenty embryos were placed on each plate of medium. Three days later the immature embryos were transferred to the same medium but containing an additional 15% sucrose in order to plasmolyze the tissue prior to gene delivery.
Plasmids pActl-D (The Plant Cell 2:163-171, 1990) and pSOG35 were precipitated onto micrometer size gold particles using standard procedures. Each plate of embryos were shot twice with the DuPont Biolistics helium device using a burst pressure of 900 psi. A total of four target plates were bombarded using the standard 80 mesh screen and four plates were shot without the screen in place. Approximately 4 hours after bombardment the embryos were transferred back to Murashige and Skoog medium containing 3% sucrose. Approximately one month later the embryo explants with developing embryogenic callus were transferred to regeneration medium (Murashige and Skoog + 1 mg/liter NAA, 5 mg/liter GA), further containing 2 mg/liter methotrexate as a selection agent. After approximately one month, developed shoots were transferred to larger sterile containers known as "GA7s" which contained half-strength Murashige and Skoog salts, 2% sucrose, and 2 mg liter methotrexate.
DNA was extracted from four plants isolated and grown as described. PCR analysis for the presence of the 35S promoter showed that two plants were positive. These transgenic plants were labelled SJ30-44 and SJ30-121. Plant SJ30-121 was assayed for Gus activity and shown to be strongly positive. The plants were transferred to soil for propagation in the greenhouse. Fertile transformed plants were obtained.
XIV: Transformation of wheat by microprojectile bombardment of immature embryos using a high maltose plasmolysis step prior to gene delivery.
Immature embryos (0.75-1.0 mm length) of gentotype UC703 were plated on Murashige and Skoog medium containing 3 mg/1 2,4-D and 3% sucrose. After approximately 4 hours the embryos were plated with the embryo axis side down onto plates containing Murashige and Skoog medium with 15% maltose, 3% sucrose and 3 mg/1 2,4-D overlayed with a filter paper supported slab of agarose containing the same components. The embryos were allowed to plasmolyze for 2-3 hours before bombardment. DNA of pActl-D (The Plant Cell 2:163-171, 1990) and pSOG35 was precipitated onto micrometer size gold particles using standard procedures. Four target plates with 20 embryos per target were shot twice with the DuPont Biolistics helium device using a burst pressure of 1100 psi. The plates were shot with an 80 mesh screen in place between the carrier stage and the target. The targets were placed in the dark at 26°C for 24 hours after bombardment before the slabs with the embryos were laid onto plates containing Murashige and Skoog medium with 3 mg/1 2,4-D and 3% sucrose. The individual embryos were removed from the slabs and placed directly on fresh medium of the same composition after another 48 hours.
Approximately 6 weeks after gene delivery, the responding tissue was placed on Murashige and Skoog medium with 3 mg/1 2,4-D and 3% sucrose with 0.2 mg/1 methotrexate for a 3 week period. The tissue was then placed on a regeneration medium comprised of Murashige and Skoog medium with 1 mg/1 zeatin riboside and 1 mg/1 methotrexate. After 2 weeks, regenerating plantlets were placed in sterile containers called "GA7s" with half-strength Murashige and Skoog salts, 2% sucrose, 1 mg/1 NAA and either 4 or 8 mg/1 methotrexate.
DNA was extracted from leaf tissue of four plants derived from 2 different target plates and PCR was run for the the presence of the dhfr gene. All 4 were positive for the presence of the dhfr. Two of the plants were sent to the greenhouse for propagation. XV: Development of improved embryogenic cultures of wheat using previously regenerated material as a culture source.
To use regenerated plants as the starting material for such improved cultures plants were regenerated from the maltose-induced friable callus described above on a Murashige and Skoog medium with 3 mg/1 BAP and 3% sucrose. This maltose-induced friable callus was a Type II cell culture labelled UC703-0612, thawed out from cryopreservation and placed on a maintenance medium (Murashige and Skoog medium + 1 mg/1 2,4-D + 3% sucrose) prior to regeneration. For embryo culture, wheat spikes were collected from the regenerated plants, sterilized with 10% Clorox solution for 10 min, and rinsed several times with sterile water. Immature embryos, 1-2 mm in size, were removed from caryopses under a dissecting microscope and cultured on a Murashige and Skoog medium with either 5 or 10 mg/1 2,4-D and 13.7 g /l maltose, or on a Murashige and Skoog medium with 2 mg/1 2,4-D and 3% sucrose. This newly induced friable callus, now recycled, was transferred to a Murashige and Skoog medium with 1 mg/1 2,4-D and 3% sucrose for maintenance or bombardment experiments. The above plant regeneration and callus induction process were then repeated to produce future generations of friable callus. As a control, embryos from wild-type plants were collected and cultured on the same maltose medium. The induction frequency of a friable and embryogenic callus from the embryos was recorded and are shown below.
Figure imgf000019_0001
To use seed derived from regenerated plants as the starting material, a Type II cell culture (UC703-0612),which was produced from an embryo grown on a maltose-containing medium, was thawed out from cryopreservation and placed on a maintenance medium (Murashige and Skoog medium + 1 mg/1 2,4-D + 3% sucrose). The callus was then placed on a medium containing Murashige and Skoog basal salts and 3 mg/1 6-BAP for plant regeneration. Seeds were harvested from the regenerated plants arid then germinated in soil. For embryo culture, wheat spikes were collected from the seed-derived plants, sterilized with 10% Clorox solution for 10 min, and rinsed several times with sterile water. Immature embryos, 1-2 mm in size, were removed from caryopses under a dissecting microscope and cultured on a Murashige and Skoog medium with 2 or 10 mg/1 2,4-D and 13.7 g /l maltose, or on a MS medium with 2 mg/1 2,4-D and 3% sucrose. The induced friable callus was transferred to a MS medium with 1 mg/1 2,4-D and 3% sucrose for maintenance or bombardment experiments.
As a control, embryos from wild-type plants were collected and cultured on the same maltose medium. The induction frequencies of friable and embryogenic callus from the embryos were recorded and are shown below.
% Embryos Produced Friable Callus
12 20 24 20 20
20
Figure imgf000020_0001
0
XVI: Transformation of wheat using a recycled embryogenic culture.
A recycled, embryogenic callus line labelled 0612RC was developed as described in the above example. Callus was prepared for bombarding by stirring and plasmolyzing for 2-3 hours in liquid Murashige and Skoog medium containing lmg/1 2,4-D, 3% sucrose and 0.6M sorbitol in a ratio of 1 part cells to 16 parts medium. Each target was prepared by using a vacuum filter appartus to affix 3ml of the cell mixture to glass fiber filters which were then placed onto solid Murashige and Skoog medium with 1 mg/1 2,4-D, 3% sucrose and 0.4M sorbitol.
DNA from plasmid pTG48 (ant43/Gus/35Sdhfr) was precipitated onto micrometer size gold particles using 0.1M CaCl2 and 0.1M Na^PO
Each target was shot twice with the microprojectile device described in WO 93/07256 using a gas pressure of 1900 psi. After gene delivery, the filters and cells were removed from the sorbitol medium and placed on Murashige and Skoog medium with 1 mg/1 2,4-D and 3% sucrose approximately 24 hours later and allowed to grow for 17 days before placing on the same medium but with lmg/1 methotrexate included. The selection level was increased to 2 mg/1 methotrexate 17 days later.
Approximately 7 weeks later colonies were removed from the original selection plates to fresh medium containing 1 mg/1 methotrexate. The colonies were identified as being positive for the presence of the dhfr gene by PCR. The tissue was bulked up and maintained on a reduced 2,4-D level (0.5 mg/1) to encourage somatic embryo maturation. Plantlets were regenerated by using Murashige and Skoog medium with 5 mg/1 GA and 1 mg/1 NAA. Some tissue was regenerated by placing on Osmorafts in liquid Murashige and Skoog media with 3% sucrose and 10 mg/1 zeatin. Plantlets were transferred to sterile containers called "GA7s" containing 1/2-strength Murashige and Skoog salts, 2% sucrose and 0.5 mg/1 NAA approximately 20 weeks after bombardment. Plants were transferred to the greenhouse for propagation. Five plants were analyzed by Southerns and the presence of the dhfr gene was confirmed.
All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims. - 19 a - INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule I3bis)
A. The indications made below relate to the microorganism referred to in the description on page 11 . , line 29
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet I
Name of depositary institution
Agricultural Research Culture
Collection ( RRL)
International Depositary Authority
Address of depositary institution (including postal code and country)
1815 N. University Street Peoria, Illinois 61604 USA
Date of deposit Accession Number
16 June 1992 ( 16.06.92) NRRL B- 18978
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet Q
We request the Expert Solution where available
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)
The indications listed below will be submitted to the International Bureau later (specify the general nature of theindications eg., "Accession Number of Deposit")
For Intemationai Bureau use only
I { This sheet was received by the International Bureau on:
Authorized officer
Figure imgf000022_0001

Claims

- 20 -What is claimed is:
1. A method for producing stably transformed fertile wheat plants, said method comprising:
(a) obtaining wheat tissue;
(b) bombarding said tissue with a DNA sequence of interest;
(c) selecting for transformed cells; and,
(d) regenerating fertile transformed plants, wherein said tissue is selected from callus, embryos, anthers, inflorescence, microspores, suspension cells and recycled lines.
2. The method of claim 1, wherein said callus tissue is selected from Type M callus, Type I callus and Type II callus.
3. The method of claim 2, wherein said callus tissue is Type II callus.
4. The method of claim 2, wherein said callus tissue is Type M callus.
5. The method of claim 3, wherein said Type II callus is derived from immature embryos, inflorescence, anthers, or leaves.
6. The method of claim 5, wherein said Type II callus is derived from immature embryos.
7. The method of claim 5, wherein said Type II callus is derived on a maltose-containing medium.
8. The method of claim 1 , wherein said tissue is embryos.
9. The method of claim 1 , wherein said tissues is recycled lines.
10. The method of claim 1, wherein said bombarding comprises subjecting the tissue to multiple shots of DNA coated particles.
11. The method of claim 1, wherein said method further comprises a plasmolysis treatment before bombardment. 21
12. The method of claim 1, wherein said method further comprises a plasmolysis treatment after bombardment.
13. The method of claim 1, wherein said method further comprises a plasmolysis treatment both before and after bombardment.
14. The method of claim 1, wherein said selecting step involvs growing transformed tissue on medium comprising methotrexate or hygromycin.
15. The method of claim 14, wherein said medium comprises methotrexate.
16. The method of claim 10, wherein said particles are coated with about 1 μg DNA per weight of the particles.
17. A method for producing stably transformed fertile wheat plants, said method comprising:
(a) obtaining Type II callus tissue from wheat tissue;
(b) bombarding said tissue with particles coated with a DNA sequence of interest which comprises a dhfr gene;
(c) growing said bombarded tissue on medium containing methotrexate to select for transformed tissue;
(d) regenerating fertile transformed plants from said transformed tissue.
18. The method of claim 17, wherein said Type II callus tissue is derived from immature embryos, inflorescence, anthers or leaves.
19. The method of claim 18, wherein said Type II callus is derived from immature embryo.
20. The method of claim 19, wherein said Type H callus is derived on a maltose-containing medium.
21. The method of claim 17, wherein said dhfr gene is a bacterial gene. - 22
22. The method of claim 17, wherein said method further comprises a plasmolysis treatment before bombardment.
23. The method of claim 17, wherein said method further comprises a plasmolysis treatment after bombardment.
24. The method of claim 17, wherein said method further comprises a plasmolysis treatment both before and after bombardment.
25. A stably transformed fertile wheat plant.
26. A stably transformed fertile wheat plant wherein said plant is produced by the method of claim 1.
27. A stably transformed fertile wheat plant according to claim 25, wherein said plant expresses a transformed gene specifically in anthers.
28. Seed, progeny, and tissue cultures of the plant of claim 25.
29. A method for producing type M callus, said method comprising growing wheat tissue on a medium containing at least 11% maltose.
30. The method of claim 29, wherein said tissue is selected from immature embryos, inflorescence, anthers or leaves.
31. The method of claim 30, wherein said tissue is immature embryos.
PCT/US1993/012085 1992-12-16 1993-12-13 Methods for stable transformation of wheat Ceased WO1994013822A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU57493/94A AU688297B2 (en) 1992-12-16 1993-12-13 Methods for stable transformation of wheat
EP94903608A EP0674715B2 (en) 1992-12-16 1993-12-13 Methods for stable transformation of wheat
DK94903608T DK0674715T4 (en) 1992-12-16 1993-12-13 Process for stable wheat transformation
DE69325389T DE69325389T3 (en) 1992-12-16 1993-12-13 Process for the stable transformation of wheat
CA002151127A CA2151127C (en) 1992-12-16 1993-12-13 Methods for stable transformation of wheat
GR990402132T GR3031054T3 (en) 1992-12-16 1999-08-23 Methods for stable transformation of wheat.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US99239192A 1992-12-16 1992-12-16
US07/992,391 1992-12-16
US08/147,261 US5610042A (en) 1991-10-07 1993-11-01 Methods for stable transformation of wheat
US08/147,261 1993-11-01

Publications (2)

Publication Number Publication Date
WO1994013822A2 true WO1994013822A2 (en) 1994-06-23
WO1994013822A3 WO1994013822A3 (en) 1994-09-15

Family

ID=26844765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/012085 Ceased WO1994013822A2 (en) 1992-12-16 1993-12-13 Methods for stable transformation of wheat

Country Status (10)

Country Link
US (2) US5610042A (en)
EP (1) EP0674715B2 (en)
AT (1) ATE181364T1 (en)
AU (1) AU688297B2 (en)
CA (1) CA2151127C (en)
DE (1) DE69325389T3 (en)
DK (1) DK0674715T4 (en)
ES (1) ES2134925T5 (en)
GR (1) GR3031054T3 (en)
WO (1) WO1994013822A2 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709462A3 (en) * 1994-10-26 1997-01-02 Monsanto Co Fast and efficient regeneration of transgenic plants
WO1998004723A1 (en) * 1996-07-26 1998-02-05 Regents Of The University Of Minnesota Fertile transgenic oat plants
WO1998048613A1 (en) * 1997-04-29 1998-11-05 The Regents Of The University Of California Compositions and methods for plant transformation and regeneration
WO1999015003A1 (en) * 1997-09-24 1999-04-01 The Regents Of The University Of California Methods and compositions for transformation of cereals using cultured shoot meristematic tissue
US6002068A (en) * 1996-12-19 1999-12-14 Novartis Finance Corporation Methods for conferring insect resistance to a monocot using a perioxidase coding sequence
US6642437B1 (en) 1997-09-30 2003-11-04 The Regents Of The University Of California Production of proteins in plant seeds
WO2005123926A1 (en) 2004-06-18 2005-12-29 Thomas Schmulling Method for modifying plant morphology, biochemistry and physiology comprising expression of cytokinin oxydase in the seeds
US7026528B2 (en) 1996-06-21 2006-04-11 Monsanto Technology Llc Methods for the production of stably-transformed, fertile wheat employing agrobacterium-mediated transformation and compositions derived therefrom
US7102056B1 (en) 1997-04-29 2006-09-05 The Regents Of The University Of California Compositions and methods for plant transformation and regeneration
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
US7429691B2 (en) 2002-09-03 2008-09-30 The Regents Of The University Of California Methods and compositions for transformation and regeneration of maize
EP2078455A1 (en) 2001-03-06 2009-07-15 The Dow Chemical Company Plant cell having animal-type sugar chain adding function
US7667099B2 (en) 2002-06-20 2010-02-23 Board Of Trustees Of Michigan State University Plastid division and related genes and proteins, and methods of use
US7781648B2 (en) 2005-05-18 2010-08-24 Board Of Trustees Of Michigan State University Resistance to soybean aphid in early maturing soybean germplasm
US7834244B2 (en) 2004-12-21 2010-11-16 Huazhong Agricultural University Transcription factor gene OsNACx from rice and use thereof for improving plant tolerance to drought and salt
EP2258856A1 (en) 1998-02-20 2010-12-08 Syngenta Limited Hybrid seed production
EP2290084A2 (en) 2003-06-30 2011-03-02 Commonwealth Scientific and Industrial Research Organization Wheat with altered branching enzyme activity and starch and starch containing products derived therefrom
EP2390333A1 (en) 2002-07-23 2011-11-30 Novozymes Biopharma DK A/S Polypeptides comprising a modified human serum albumin secretion pre-sequence with improved secretion yield
WO2013005211A2 (en) 2011-07-05 2013-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Boron complexing plant materials and uses thereof cross-reference to related applications
US8362318B2 (en) 2008-12-18 2013-01-29 Board Of Trustees Of Michigan State University Enzyme directed oil biosynthesis in microalgae
EP2666867A1 (en) 2006-07-12 2013-11-27 The Board Of Trustees Operating Michigan State University DNA encoding ring zinc-finger protein and the use of the DNA in vectors and bacteria and in plants
US8674176B2 (en) 2003-05-29 2014-03-18 Ingo H. Heilmann ADS genes for reducing saturated fatty acid levels in seed oils
US9133475B2 (en) 2008-11-26 2015-09-15 Board Of Trustees Of Michigan State University Aphid resistant soybean plants
US9187761B2 (en) 2006-09-25 2015-11-17 Thomas Schmulling Transcriptional repressors of cytokinin signaling and their use
WO2016039961A1 (en) 2014-09-11 2016-03-17 Marrone Bio Innovations, Inc Chromobacterium subtsugae genome
US9307708B2 (en) 2014-03-07 2016-04-12 Pioneer Hi-Bred International Inc Systems for extracting monocot embryos
US9328335B2 (en) 2009-12-30 2016-05-03 Board Of Trustees Of Michigan State University Method to produce acetyldiacylglycerols (ac-TAGs) by expression of an acetyltransferase gene isolated from Euonymus alatus (burning bush)
US10253329B2 (en) 2013-01-04 2019-04-09 Board Of Trustees Of Michigan State University Sources of aphid resistance in soybean plants
US10392629B2 (en) 2014-01-17 2019-08-27 Board Of Trustees Of Michigan State University Increased caloric and nutritional content of plant biomass

Families Citing this family (233)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5610042A (en) * 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US6872871B2 (en) * 1998-02-02 2005-03-29 Odyssey Thera Inc. Mapping molecular interactions in plants with protein fragments complementation assays
MX257801B (en) 1997-06-02 2008-06-10 Syngenta Participations Ag Plant transformation methods
US6060315A (en) * 1997-12-01 2000-05-09 Lockheed Martin Energy Research Corporation Method for facilitating the introduction of material into cells
US6153811A (en) * 1997-12-22 2000-11-28 Dekalb Genetics Corporation Method for reduction of transgene copy number
US5973227A (en) * 1998-05-06 1999-10-26 University Of Saskatchewan Flax transformation
US7897843B2 (en) 1999-03-23 2011-03-01 Mendel Biotechnology, Inc. Transcriptional regulation of plant biomass and abiotic stress tolerance
US20050086718A1 (en) 1999-03-23 2005-04-21 Mendel Biotechnology, Inc. Plant transcriptional regulators of abiotic stress
CN1423520B (en) 1999-11-10 2011-05-04 安·斯雷德 Compositions and methods for regulating plant cell division
AU780463B2 (en) 1999-11-17 2005-03-24 Mendel Biotechnology, Inc. Environmental stress tolerance genes
EP1950306A1 (en) 1999-11-17 2008-07-30 Mendel Biotechnology, Inc. Environmental stress tolerance genes
US6812028B1 (en) * 1999-12-10 2004-11-02 University Of Guelph Embryogenesis and plant regeneration from microspores
US6580019B1 (en) 2000-03-09 2003-06-17 Dekalb Genetics Corporation Non-reciprocal recombination-mediated transgene deletion in transgenic plants
US6750379B2 (en) 2000-03-09 2004-06-15 Dekalb Genetics Corporation Homologous recombination-mediated transgene alterations in plants
US6806399B1 (en) * 2000-04-19 2004-10-19 Carmel-Haifa University Economic Corporation Ltd. Pollen-mediated method for transformation of maize, tomato or melon
US6995016B2 (en) 2000-08-17 2006-02-07 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Process for inducing direct somatic embryogenesis in immature scutella cells of pooideae, and rapidly regenerating fertile plants
WO2002015675A1 (en) 2000-08-22 2002-02-28 Mendel Biotechnology, Inc. Genes for modifying plant traits iv
FR2815969B1 (en) 2000-10-30 2004-12-10 Aventis Cropscience Sa TOLERANT PLANTS WITH HERBICIDES BY METABOLIC BYPASS
EP1465988A4 (en) 2001-03-19 2005-08-03 Cargill Inc Myo-inositol oxygenases
JP2004532213A (en) * 2001-04-06 2004-10-21 ザ ユニヴァーシティ オヴ シカゴ Chemotherapy induction of EGR-1 promoter activity
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
JP4338402B2 (en) 2001-05-22 2009-10-07 ユニバーシティ オブ シカゴ N4 virus single-stranded DNA-dependent RNA polymerase
US20050287647A9 (en) 2001-05-30 2005-12-29 Carl Perez Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes
ATE536100T1 (en) 2001-10-26 2011-12-15 Baylor College Medicine COMPOSITION FOR ALTERING BONE PROPERTIES IN A SUBJECT
CA2469310C (en) 2001-12-11 2013-01-29 Advisys, Inc. Plasmid mediated supplementation for treating chronically ill subjects
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003064626A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
BRPI0311324B1 (en) 2002-05-22 2020-01-28 Monsanto Technology Llc polynucleotide, vector, polypeptide with desasturase activity, methods for plant production and corn oil containing omega-3 fatty acids, to increase the nutritional value of an edible product, food or feed manufacture, as well as edible composition
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US6916474B2 (en) 2002-07-15 2005-07-12 Board Of Regents, The University Of Texas System Antibodies with increased affinities for anthrax antigens
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
KR101170653B1 (en) 2002-08-12 2012-08-03 제네렉스, 인코포레이티드 Methods and compositions concerning poxviruses and cancer
BR0314389A (en) 2002-09-18 2005-07-12 Mendel Biotechnology Inc Plant polynucleotides and polypeptides
EP2933334B1 (en) * 2003-02-18 2019-09-18 Baylor College of Medicine Induced activation in dendritic cells
TW200424214A (en) * 2003-04-21 2004-11-16 Advisys Inc Plasmid mediated GHRH supplementation for renal failures
EP1788861B1 (en) 2004-08-24 2017-04-12 Monsanto Technology, LLC Adenylate translocator protein gene non-coding regulatory elements for use in plants
BRPI0517462A (en) 2004-10-21 2008-10-07 Charles L Niblett methods and materials for conferring resistance to plant pests and pathogens
AU2005333165B2 (en) 2004-11-12 2012-07-19 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
AR053269A1 (en) 2005-05-16 2007-04-25 Monsanto Technology Llc CORN PLANTS AND SEEDS WITH IMPROVEMENT OF ASPARAGIN AND PROTEIN
KR20080052570A (en) 2005-07-29 2008-06-11 타게티드 그로스 인코퍼레이티드 Dominant Negative Mutation of RPRP Protein Protection of Active Cyclin-CDV Complex Inhibition by Wild-type RPP
US9180149B2 (en) * 2005-09-07 2015-11-10 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20070059833A1 (en) * 2005-09-07 2007-03-15 Maxcyte, Inc. Use of Nucleases to Improve Viability and Enhance Transgene Expression in Transfected Cells
ATE546537T1 (en) 2005-12-15 2012-03-15 Targeted Growth Inc INCREASED SEED SIZE AND SEED NUMBER DUE TO TRANSGENIC OVEREXPRESSION OF A GROWTH AND/OR DEVELOPMENT GENE DURING EARLY EMBYROD DEVELOPMENT
US7663020B2 (en) * 2006-01-11 2010-02-16 Agrinomics Llc Generation of plants with altered oil content
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US7868228B2 (en) 2006-01-31 2011-01-11 Monsanto Technology Llc Phosphopantetheinyl transferases from bacteria
US7820883B2 (en) * 2006-03-15 2010-10-26 Dow Agrosciences Llc Resistance to auxinic herbicides
DE602007010113D1 (en) 2006-03-31 2010-12-09 Reliance Life Sciences Pvt Ltd Direct regeneration of young plants of the species Jathropha curcas
WO2008014484A1 (en) 2006-07-27 2008-01-31 University Of Maryland, Baltimore Cellular receptor for antiproliferative factor
CA2921063C (en) 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
EP2465510B1 (en) * 2006-10-19 2018-11-28 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptors and adaptors thereof
BRPI0717474A2 (en) 2006-10-20 2014-03-11 Arizona Board Of Regentes For And On Behalf Of Arizona State University Modified cyanobacteria
WO2008061156A2 (en) 2006-11-15 2008-05-22 Agrigenetics, Inc. Generation of plants with altered protein, fiber, or oil content
WO2008079545A2 (en) * 2006-11-15 2008-07-03 Agrigenetics, Inc. Generation of plants with altered protein, fiber, or oil content
US8034993B2 (en) * 2006-11-15 2011-10-11 Dow Agrosciences Llc Generation of plants with altered protein, fiber, or oil content
CA2669676C (en) * 2006-11-15 2018-01-23 Agrigenetics, Inc. Generation of plants with altered protein, fiber, or oil content
US8106253B2 (en) * 2006-11-15 2012-01-31 Agrigenetics, Inc. Generation of plants with altered protein, fiber, or oil content
WO2008067547A2 (en) 2006-11-30 2008-06-05 Research Development Foundation Improved immunoglobulin libraries
EP2115150A4 (en) * 2006-12-15 2010-06-02 Agrinomics Llc Generation of plants with altered oil, protein, or fiber content
US7563943B2 (en) * 2006-12-15 2009-07-21 Agrinomics Llc Generation of plants with altered oil, protein, or fiber content
WO2008076831A2 (en) * 2006-12-15 2008-06-26 Agrinomics Llc Generation of plants with altered oil, protein, or fiber content
US7790954B2 (en) * 2006-12-15 2010-09-07 Agrigenetics, Inc. Generation of plants with altered oil, protein, or fiber content
MX2009006465A (en) * 2006-12-15 2009-08-21 Agrinomics Llc Generation of plants with altered oil, protein, or fiber content.
KR20080084528A (en) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. Oncolytic Vaccinia Virus Cancer Treatment
CA2685675C (en) 2007-05-01 2016-02-16 Research Development Foundation Immunoglobulin fc libraries
BRPI0813098A2 (en) * 2007-06-18 2014-11-11 Agrinomics Llc GENERATION OF PLANTS WITH CHANGED OIL, PROTEIN OR FIBER
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
CA2711499C (en) 2008-01-10 2018-09-25 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
US9746471B2 (en) 2008-01-25 2017-08-29 Multivir Inc. P53 biomarkers
KR101648019B1 (en) 2008-06-04 2016-08-16 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Methods for the production of iPS cells using non-viral approach
WO2010019569A1 (en) 2008-08-12 2010-02-18 Cellular Dynamics International. Inc. Methods for the production of ips cells
CA2734325A1 (en) 2008-08-18 2010-02-25 University Of Maryland, Baltimore Derivatives of apf and methods of use
US20100203067A1 (en) 2008-09-22 2010-08-12 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
US20110262477A1 (en) 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
CA2737595C (en) 2008-10-14 2017-09-12 Monsanto Technology Llc Utilization of fatty acid desaturases from hemiselmis spp.
JP5651125B2 (en) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド MEK mutations that confer resistance to MEK inhibitors
WO2010084488A1 (en) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
WO2010096510A2 (en) 2009-02-17 2010-08-26 Edenspace Systems Corporation Tempering of cellulosic biomass
HRP20160274T1 (en) 2009-04-03 2016-04-08 University Of Chicago PREPARATIONS AND METHODS RELATED TO PROTEIN A (SPA) VARIATIONS
EP2424885B1 (en) 2009-04-28 2016-03-23 Vanderbilt University Compositions and methods for the treatment of disorders involving epithelial cell apoptosis
WO2010138971A1 (en) 2009-05-29 2010-12-02 Edenspace Systems Corporation Plant gene regulatory elements
CA2764373C (en) 2009-06-05 2019-11-19 FUJIFILM Cellular Dynamics, Inc. Reprogramming t cells and hematophietic cells
CA2772298A1 (en) 2009-08-26 2011-03-03 Research Development Foundation Methods for creating antibody libraries
WO2011032180A1 (en) 2009-09-14 2011-03-17 Jennerex, Inc. Oncolytic vaccinia virus combination cancer therapy
WO2011050271A1 (en) 2009-10-23 2011-04-28 Monsanto Technology Llc Methods and compositions for expression of transgenes in plants
BR112012013664B1 (en) 2009-12-10 2020-11-10 Turnstone Limited Partnership oncolitic rhabdovirus
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
RU2571930C2 (en) 2010-02-25 2015-12-27 Дана-Фарбер Кэнсер Инститьют, Инк. Braf mutations ensuing resistance to braf inhibitors
EP3214174B1 (en) 2010-03-04 2019-10-16 InteRNA Technologies B.V. A mirna molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with emt
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
US9249195B2 (en) 2010-04-07 2016-02-02 Vanderbilt University Reovirus vaccines and methods of use therefor
EP2560672B1 (en) 2010-04-19 2014-03-05 Research Development Foundation Rtef-1 variants and uses thereof
US20110289625A1 (en) 2010-05-19 2011-11-24 Rujin Chen Altered leaf morphology and enhanced agronomic properties in plants
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
EP3889254B8 (en) 2010-06-09 2024-10-02 Dana-Farber Cancer Institute, Inc. A mek1 mutation conferring resistance to raf and mek inhibitors
ES2670842T5 (en) 2010-06-15 2024-12-16 Fujifilm Cellular Dynamics Inc Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2011159797A2 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. A compendium of ready-built stem cell models for interrogation of biological response
EP2588120B1 (en) 2010-07-02 2017-11-15 The University of Chicago Compositions and methods related to protein a (spa) variants
EP3369817A1 (en) 2010-07-06 2018-09-05 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma , or in diseases or conditions with activated braf pathway
WO2012006440A2 (en) 2010-07-07 2012-01-12 Cellular Dynamics International, Inc. Endothelial cell production by programming
WO2012018933A2 (en) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
EP2618829B1 (en) 2010-09-22 2019-05-01 The Regents of the University of Colorado, a body corporate Smad7 for use in the treatment of oral mucositis or psoriasis
WO2012061615A1 (en) 2010-11-03 2012-05-10 The Samuel Roberts Noble Foundation, Inc. Transcription factors for modification of lignin content in plants
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
CA2826467C (en) 2011-02-07 2019-11-12 Research Development Foundation Engineered immunoglobulin fc polypeptides
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
EP2694534B1 (en) 2011-04-08 2018-06-20 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US8901371B2 (en) 2011-05-06 2014-12-02 The Samuel Roberts Noble Foundation, Inc. Compositions and methods for improved plant feedstock
WO2012170304A2 (en) 2011-06-02 2012-12-13 The Regents Of The University Of California Plants with elevated levels of glucan
CA2872045A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
CA2841165A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
WO2013025834A2 (en) 2011-08-15 2013-02-21 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
WO2013053899A1 (en) 2011-10-12 2013-04-18 Moeller Niels Iversen Peptides derived from campylobacter jejuni and their use in vaccination
ES2886147T3 (en) 2011-12-22 2021-12-16 Interna Tech B V MiRNAs for the treatment of head and neck cancer
JP6251730B2 (en) 2012-04-26 2017-12-20 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during STAPHYLOCOCUSAUREUS disease
HRP20201127T1 (en) 2012-04-26 2020-11-27 University Of Chicago STAPHYLOCOCCAL COAGULASE ANTIGENS AND METHODS OF APPLICATION
MX360824B (en) 2012-07-31 2018-11-15 Univ Texas Methods and compositions for in vivo induction of pancreatic beta cell formation.
FI3622810T3 (en) 2012-09-24 2024-03-21 Seminis Vegetable Seeds Inc METHODS AND COMPOSITIONS FOR EXTENDING THE SHELF LIFE OF PLANT PRODUCTS
US9890216B2 (en) 2012-10-23 2018-02-13 Board Of Regents, The University Of Texas System Antibodies with engineered IgG Fc domains
EP3800256A1 (en) 2012-11-06 2021-04-07 InteRNA Technologies B.V. Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
WO2014116721A1 (en) 2013-01-22 2014-07-31 The Arizona Board Of Regents For And On Behalf Of Arizona State University Geminiviral vector for expression of rituximab
RU2684211C2 (en) 2013-02-21 2019-04-04 Тёрнстоун Лимитед Партнершип Vaccine composition
WO2014130770A1 (en) 2013-02-22 2014-08-28 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
EP2961386B1 (en) 2013-02-28 2019-07-10 The General Hospital Corporation Mirna profiling compositions and methods of use
WO2014132137A2 (en) 2013-03-01 2014-09-04 Université De Genève Transgenic cell selection
JP6576251B2 (en) 2013-03-08 2019-09-18 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate PTD-Smad7 drug therapy
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
US9944690B2 (en) 2013-03-14 2018-04-17 Bellicum Pharmaceuticals, Inc. Methods for controlling T cell proliferation
EP3004329B1 (en) 2013-06-05 2020-03-04 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
US11819555B2 (en) 2013-09-09 2023-11-21 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
CA2929555A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure
WO2015070009A2 (en) 2013-11-08 2015-05-14 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
ES3012932T3 (en) 2013-12-03 2025-04-10 Evaxion Biotech As Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
EP3099719B1 (en) 2014-01-29 2020-04-01 Dana-Farber Cancer Institute, Inc. Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
WO2015123561A2 (en) 2014-02-14 2015-08-20 University Of Utah Research Foundation Methods and compositions for inhibiting retinopathy of prematurity
CA2937750A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
US20170037091A1 (en) 2014-02-25 2017-02-09 Research Development Foundation Sty peptides for inhibition of angiogenesis
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
AR100874A1 (en) 2014-06-16 2016-11-09 Consejo Nac De Investig Científicas Y Técnicas (Conicet) CHEMICAL GENES AND PROTEINS OF OXIDATIVE RESISTANCE, AND TRANSGENIC PLANTS THAT INCLUDE THE SAME
EP3189148A4 (en) 2014-09-02 2018-05-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
ES2904301T3 (en) 2014-11-03 2022-04-04 Academisch Ziekenhuis Leiden H O D N Leids Univ Medisch Centrum Anti-Bob1 T cell receptors and uses thereof
CA2974716A1 (en) 2014-11-12 2016-05-19 Nmc, Inc. Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
WO2016075305A2 (en) 2014-11-13 2016-05-19 Evaxion Biotech Aps Peptides derived from acinetobacter baumannii and their use in vaccination
ES2743232T3 (en) 2014-12-15 2020-02-18 Bellicum Pharmaceuticals Inc Methods for the activation or controlled elimination of therapeutic cells
EP3244918A2 (en) 2015-01-12 2017-11-22 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae
EP3250675A1 (en) 2015-01-28 2017-12-06 SABIC Global Technologies B.V. Methods and compositions for high-efficiency production of biofuel and/or biomass
US10457737B2 (en) 2015-02-09 2019-10-29 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
US11421229B2 (en) 2015-02-20 2022-08-23 Baylor College Of Medicine p63 inactivation for the treatment of heart failure
EP4219544A1 (en) 2015-03-10 2023-08-02 Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
US20180201656A1 (en) 2015-07-04 2018-07-19 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting Pseudomonas Aeruginosa
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
AU2016342179B2 (en) 2015-10-20 2022-08-18 FUJIFILM Cellular Dynamics, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
JP6983771B2 (en) 2015-10-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California A method for producing T cells from stem cells and an immunotherapeutic method using the T cells.
WO2017079202A1 (en) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP3373968B1 (en) 2015-11-09 2024-04-17 The Children's Hospital of Philadelphia Glypican 2 as a cancer marker and therapeutic target
WO2017144523A1 (en) 2016-02-22 2017-08-31 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
WO2017168348A1 (en) 2016-03-31 2017-10-05 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
WO2017216384A1 (en) 2016-06-17 2017-12-21 Evaxion Biotech Aps Vaccination targeting ichthyophthirius multifiliis
WO2017220787A1 (en) 2016-06-24 2017-12-28 Evaxion Biotech Aps Vaccines against aearomonas salmonicida infection
CA3029582A1 (en) 2016-07-01 2018-01-04 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
US11414464B2 (en) 2016-07-22 2022-08-16 Evaxion Biotech A/S Chimeric proteins for inducing immunity towards infection with S. aureus
US9963498B2 (en) 2016-08-18 2018-05-08 Wisconsin Alumni Research Foundation Peptides that inhibit syndecan-1 activation of VLA-4 and IGF-1R
US11147221B2 (en) 2016-08-22 2021-10-19 Biolumic Limited Methods of seed treatment and resulting products
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
CN110050061A (en) 2016-10-05 2019-07-23 富士胶片细胞动力公司 The mature pedigree of generation is induced multi-potent stem cell from what is destroyed with MeCP2
CN110023491B (en) 2016-10-05 2024-03-08 富士胶片细胞动力公司 Methods for directed differentiation of pluripotent stem cells into HLA homozygous immune cells
RU2646108C1 (en) * 2016-12-07 2018-03-01 Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН Method for obtaining transgenic wheat plants using bioballistics
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
EP3565576A1 (en) 2017-01-05 2019-11-13 Evaxion Biotech ApS Vaccines targeting pseudomonas aeruginosa
US11371056B2 (en) 2017-03-07 2022-06-28 BASF Agricultural Solutions Seed US LLC HPPD variants and methods of use
CA3055389A1 (en) 2017-03-07 2018-09-13 BASF Agricultural Solutions Seed US LLC Hppd variants and methods of use
IL269716B2 (en) 2017-04-18 2025-07-01 Fujifilm Cellular Dynamics Inc Activated cells specific antibody immunity
US20210147507A1 (en) 2017-05-09 2021-05-20 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
US20220185849A1 (en) 2017-05-19 2022-06-16 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
AU2018293468A1 (en) 2017-06-29 2020-01-30 Biolumic Limited Method to improve crop yield and/or quality
WO2019038594A2 (en) 2017-08-21 2019-02-28 Biolumic Limited High growth and high hardiness transgenic plants
US11634725B2 (en) 2017-11-03 2023-04-25 University Of Florida Research Foundation, Inc. Methods and compositions for plant pathogen resistance in plants
AU2018358016A1 (en) 2017-11-03 2020-05-07 Interna Technologies B.V. MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
US11612618B2 (en) 2017-11-14 2023-03-28 Henry Ford Health System Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury
EP4137578A1 (en) 2018-01-05 2023-02-22 Ottawa Hospital Research Institute Modified vaccinia vectors
WO2019145399A1 (en) 2018-01-24 2019-08-01 Evaxion Biotech Aps Vaccines for prophylaxis of s. aureus infections
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
EP3775214A2 (en) 2018-03-30 2021-02-17 University of Geneva Micro rna expression constructs and uses thereof
WO2020069313A2 (en) 2018-09-28 2020-04-02 Henry Ford Health System Use of extracellular vesicles in combination with tissue plasminogen activator and/or thrombectomy to treat stroke
WO2020083904A1 (en) 2018-10-22 2020-04-30 Evaxion Biotech Aps Vaccines targeting m. catharrhalis
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
EP3931206A1 (en) 2019-02-27 2022-01-05 Evaxion Biotech ApS Vaccines targeting h. influenzae
US20210069242A1 (en) 2019-04-18 2021-03-11 Dmitry Dmitrievich Genkin Reprogramming of polymorphonuclear leukocytes
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
CN114555807B (en) 2019-07-19 2025-05-16 费城儿童医院 Chimeric antigen receptor containing a glypican 2 binding domain
US20210147525A1 (en) 2019-10-18 2021-05-20 The Regents Of The University Of California Methods and compositions for treating pathogenic blood vessel disorders
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021140123A1 (en) 2020-01-06 2021-07-15 Evaxion Biotech Aps Vaccines targeting neisseria gonorrhoeae
BR112022024027A2 (en) 2020-05-27 2023-02-07 Antion Biosciences Sa ADAPTER MOLECULES TO REDIRECT CAR T CELLS TO AN ANTIGEN OF INTEREST
KR20230019453A (en) 2020-05-29 2023-02-08 후지필름 셀룰러 다이내믹스, 인코포레이티드 Double cell aggregates of retinal pigment epithelial cells and photoreceptors and methods of use thereof
MX2022015002A (en) 2020-05-29 2023-03-03 Fujifilm Cellular Dynamics Inc B-LAYER OF THE RETINAL PIGMENTAL EPITHELIUM AND PHOTORECEPTORS AND THEIR USE.
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
EP4570256A3 (en) 2020-11-05 2025-09-24 Board of Regents, The University of Texas System Engineered t cell receptors targeting egfr antigens and methods of use
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CA3202849A1 (en) 2021-02-09 2022-08-18 University Of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
US20240122865A1 (en) 2021-02-19 2024-04-18 Pfizer Inc. Methods of Protecting RNA
BR112023020861A2 (en) 2021-04-08 2023-12-12 Janssen Biotech Inc MATERIALS AND METHODS FOR OPTIMIZED GENETIC MODIFICATION OF MEMORY T CELLS ANALOGOUS TO STEM CELLS
US20240368541A1 (en) 2021-05-03 2024-11-07 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells
CN117716020A (en) 2021-05-07 2024-03-15 安斯泰来再生医药协会 Method for producing mature hepatocytes
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
AU2022307747A1 (en) 2021-07-05 2024-01-25 Evaxion Biotech A/S Vaccines targeting neisseria gonorrhoeae
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
US20250257388A2 (en) 2021-11-08 2025-08-14 St. Jude Children's Research Hospital, Inc. Pre-effector car-t cell gene signatures
EP4436595A1 (en) 2021-11-22 2024-10-02 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
US20250177514A1 (en) 2022-01-28 2025-06-05 Pfizer Inc. Coronavirus antigen variants
EP4493213A1 (en) 2022-03-16 2025-01-22 University of Houston System Persistent hsv gene delivery system
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
US20250288657A1 (en) 2022-05-04 2025-09-18 Evaxion Biotech A/S Staphylococcal protein variants and truncates
KR20250035053A (en) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. Multispecific molecules for modulating T cell activity and uses thereof
EP4536687A1 (en) 2022-06-08 2025-04-16 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
JP2025519556A (en) 2022-06-10 2025-06-26 リサーチ ディベロップメント ファウンデーション Engineered FcRIIb-selective IgG1 Fc variants and uses thereof
EP4547824A1 (en) 2022-06-29 2025-05-07 Fujifilm Holdings America Corporation Ipsc-derived astrocytes and methods of use thereof
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
WO2024186630A1 (en) 2023-03-03 2024-09-12 Henry Ford Health System Use of extracellular vesicles for the treatment of cancer
GB202306619D0 (en) 2023-05-04 2023-06-21 Antion Biosciences Sa Cell
WO2025050009A2 (en) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
GB202402745D0 (en) 2024-02-27 2024-04-10 Antion Biosciences Sa Cell

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801545A (en) * 1983-05-19 1989-01-31 Plant Genetics, Inc. Enhanced somatic embryogenesis using maltose
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8611818D0 (en) * 1986-05-15 1986-06-25 Shell Int Research Plant generation method
FI890917L (en) * 1988-03-02 1989-09-03 Eidgenoess Tech Hochschule FOERFARANDE FOER FRAMSTAELLNING AV TRANSGENA VAEXTER.
EP0397413B1 (en) * 1989-05-12 1994-01-12 Pioneer Hi-Bred International, Inc. Improved particle gun
EP0814166A3 (en) * 1989-08-09 1998-05-13 DeKalb Genetics Corporation Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof
EP0442174A1 (en) * 1990-02-13 1991-08-21 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
JP3234598B2 (en) * 1990-11-23 2001-12-04 プラント・ジエネテイツク・システムズ・エヌ・ベー Transformation method of monocotyledonous plant
WO1993004178A1 (en) * 1991-08-23 1993-03-04 University Of Florida A novel method for the production of transgenic plants
AU2781892A (en) * 1991-10-07 1993-05-03 Ciba-Geigy Ag Particle gun for introducing dna into intact cells
US5610042A (en) * 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
IL101119A0 (en) * 1992-03-03 1992-11-15 Univ Ramot Transgenic wheat

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521241B2 (en) 1994-08-20 2009-04-21 Gendaq Limited Regulated gene expression in plants
US5631152A (en) * 1994-10-26 1997-05-20 Monsanto Company Rapid and efficient regeneration of transgenic plants
EP0709462A3 (en) * 1994-10-26 1997-01-02 Monsanto Co Fast and efficient regeneration of transgenic plants
US6153812A (en) * 1994-10-26 2000-11-28 Monsanto Company Rapid and efficient regeneration of transgenic wheat plants
US7026528B2 (en) 1996-06-21 2006-04-11 Monsanto Technology Llc Methods for the production of stably-transformed, fertile wheat employing agrobacterium-mediated transformation and compositions derived therefrom
WO1998004723A1 (en) * 1996-07-26 1998-02-05 Regents Of The University Of Minnesota Fertile transgenic oat plants
US5773269A (en) * 1996-07-26 1998-06-30 Regents Of The University Of Minnesota Fertile transgenic oat plants
US6002068A (en) * 1996-12-19 1999-12-14 Novartis Finance Corporation Methods for conferring insect resistance to a monocot using a perioxidase coding sequence
US6235529B1 (en) 1997-04-29 2001-05-22 The Regents Of The University Of California Compositions and methods for plant transformation and regeneration
US6541257B2 (en) 1997-04-29 2003-04-01 The Regents Of The University Of California Method for preparing barley green regenerative tissue
US7102056B1 (en) 1997-04-29 2006-09-05 The Regents Of The University Of California Compositions and methods for plant transformation and regeneration
WO1998048613A1 (en) * 1997-04-29 1998-11-05 The Regents Of The University Of California Compositions and methods for plant transformation and regeneration
US6486384B1 (en) 1997-09-24 2002-11-26 The Regents Of The University Of California Methods and compositions for transformation of cereals using cultured shoot meristematic tissue
WO1999015003A1 (en) * 1997-09-24 1999-04-01 The Regents Of The University Of California Methods and compositions for transformation of cereals using cultured shoot meristematic tissue
US6642437B1 (en) 1997-09-30 2003-11-04 The Regents Of The University Of California Production of proteins in plant seeds
EP2258856A1 (en) 1998-02-20 2010-12-08 Syngenta Limited Hybrid seed production
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
US7285416B2 (en) 2000-01-24 2007-10-23 Gendaq Limited Regulated gene expression in plants
EP2078455A1 (en) 2001-03-06 2009-07-15 The Dow Chemical Company Plant cell having animal-type sugar chain adding function
US7667099B2 (en) 2002-06-20 2010-02-23 Board Of Trustees Of Michigan State University Plastid division and related genes and proteins, and methods of use
EP2390333A1 (en) 2002-07-23 2011-11-30 Novozymes Biopharma DK A/S Polypeptides comprising a modified human serum albumin secretion pre-sequence with improved secretion yield
US7429691B2 (en) 2002-09-03 2008-09-30 The Regents Of The University Of California Methods and compositions for transformation and regeneration of maize
US8674176B2 (en) 2003-05-29 2014-03-18 Ingo H. Heilmann ADS genes for reducing saturated fatty acid levels in seed oils
EP2290084A2 (en) 2003-06-30 2011-03-02 Commonwealth Scientific and Industrial Research Organization Wheat with altered branching enzyme activity and starch and starch containing products derived therefrom
WO2005123926A1 (en) 2004-06-18 2005-12-29 Thomas Schmulling Method for modifying plant morphology, biochemistry and physiology comprising expression of cytokinin oxydase in the seeds
US7834244B2 (en) 2004-12-21 2010-11-16 Huazhong Agricultural University Transcription factor gene OsNACx from rice and use thereof for improving plant tolerance to drought and salt
US8378173B2 (en) 2004-12-21 2013-02-19 Huazhong Agricultural University Transcription factor gene OsNACx from rice and use thereof for improving plant tolerance to drought and salt
US7781648B2 (en) 2005-05-18 2010-08-24 Board Of Trustees Of Michigan State University Resistance to soybean aphid in early maturing soybean germplasm
EP2666867A1 (en) 2006-07-12 2013-11-27 The Board Of Trustees Operating Michigan State University DNA encoding ring zinc-finger protein and the use of the DNA in vectors and bacteria and in plants
US9187761B2 (en) 2006-09-25 2015-11-17 Thomas Schmulling Transcriptional repressors of cytokinin signaling and their use
US9133475B2 (en) 2008-11-26 2015-09-15 Board Of Trustees Of Michigan State University Aphid resistant soybean plants
US9062331B2 (en) 2008-12-18 2015-06-23 Board Of Trustees Of Michigan State University Enzyme directed oil biosynthesis in microalgae
US8362318B2 (en) 2008-12-18 2013-01-29 Board Of Trustees Of Michigan State University Enzyme directed oil biosynthesis in microalgae
US9771605B2 (en) 2008-12-18 2017-09-26 Board Of Trustees Of Michigan State University Enzyme directed oil biosynthesis in microalgae
US9328335B2 (en) 2009-12-30 2016-05-03 Board Of Trustees Of Michigan State University Method to produce acetyldiacylglycerols (ac-TAGs) by expression of an acetyltransferase gene isolated from Euonymus alatus (burning bush)
WO2013005211A2 (en) 2011-07-05 2013-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Boron complexing plant materials and uses thereof cross-reference to related applications
US10253329B2 (en) 2013-01-04 2019-04-09 Board Of Trustees Of Michigan State University Sources of aphid resistance in soybean plants
US10392629B2 (en) 2014-01-17 2019-08-27 Board Of Trustees Of Michigan State University Increased caloric and nutritional content of plant biomass
US9307708B2 (en) 2014-03-07 2016-04-12 Pioneer Hi-Bred International Inc Systems for extracting monocot embryos
US9320210B2 (en) 2014-03-07 2016-04-26 Pioneer Hi Bred Internatonal Inc Methods of extracting monocot embryos
WO2016039961A1 (en) 2014-09-11 2016-03-17 Marrone Bio Innovations, Inc Chromobacterium subtsugae genome

Also Published As

Publication number Publication date
ES2134925T5 (en) 2007-06-01
ES2134925T3 (en) 1999-10-16
AU688297B2 (en) 1998-03-12
DE69325389T3 (en) 2007-02-08
DE69325389D1 (en) 1999-07-22
EP0674715B2 (en) 2006-10-11
WO1994013822A3 (en) 1994-09-15
DK0674715T3 (en) 1999-11-29
DE69325389T2 (en) 1999-11-25
CA2151127A1 (en) 1994-06-23
EP0674715A1 (en) 1995-10-04
GR3031054T3 (en) 1999-12-31
DK0674715T4 (en) 2007-02-19
US5955362A (en) 1999-09-21
EP0674715B1 (en) 1999-06-16
CA2151127C (en) 2008-03-25
ATE181364T1 (en) 1999-07-15
AU5749394A (en) 1994-07-04
US5610042A (en) 1997-03-11

Similar Documents

Publication Publication Date Title
AU688297B2 (en) Methods for stable transformation of wheat
US5969213A (en) Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof
EP0442174A1 (en) Stable transformation of plant cells
WO1991002071A2 (en) Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
CA2321781C (en) Particle bombardment transformation of brassica
US20240093222A1 (en) Methods for transforming corn explants
US6140555A (en) Methods for maize transformation coupled with adventitious regeneration utilizing nodal section explants and mature zygotic embryos
US6486384B1 (en) Methods and compositions for transformation of cereals using cultured shoot meristematic tissue
Abedinia et al. An efficient transformation system for the Australian rice cultivar, Jarrah
US20100281565A1 (en) Transformation of Crambe Abyssinica
EP1745132A1 (en) Methods for high efficiency transformation and regeneration of plant suspension cultures
US7429691B2 (en) Methods and compositions for transformation and regeneration of maize
US6570068B1 (en) Methods for maize transformation coupled with adventitious regeneration utilizing nodal section explants and mature zygotic embryos
CA2064761C (en) Methods and compositions for the production of stably transformed fertile monocot plants and cells thereof
US20040210958A1 (en) A Novel Culture Method for Corn Transformation
Somers et al. Genetic transformation in Avena sativa L.(oat)
Eissa Genetic Transformation via Biolistic Gene Gun Method and Regeneration of Common Bean
Gulati et al. In vitro regeneration and genetic transformation of lentil
AU723435B2 (en) Particle mediated transformation of cotton
Oneto et al. Maize Genetic Transformation: The Biolistic Protocol
Simmonds Gene transfer in the Gramineae.
SOMERS¹ et al. II. 3 Genetic Transformation in Avena sativa L.(Oat)
CA2440416A1 (en) Particle bombardment transformation of brassica

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 1994903608

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2151127

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994903608

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994903608

Country of ref document: EP